10Q

0001393905-19-000016.txt : 20190114 0001393905-19-000016.hdr.sgml : 20190114 20190114160009 ACCESSION NUMBER: 0001393905-19-000016 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 57 CONFORMED PERIOD OF REPORT: 20181130 FILED AS OF DATE: 20190114 DATE AS OF CHANGE: 20190114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cell MedX Corp. CENTRAL INDEX KEY: 0001493712 STANDARD INDUSTRIAL CLASSIFICATION: RETAIL-MISCELLANEOUS RETAIL [5900] IRS NUMBER: 383939625 STATE OF INCORPORATION: NV FISCAL YEAR END: 0531 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-54500 FILM NUMBER: 19525088 BUSINESS ADDRESS: STREET 1: 123 W. NYE LN, SUITE 446 CITY: CARSON CITY STATE: NV ZIP: 89706 BUSINESS PHONE: (844) 238-2692 MAIL ADDRESS: STREET 1: 123 W. NYE LN, SUITE 446 CITY: CARSON CITY STATE: NV ZIP: 89706 FORMER COMPANY: FORMER CONFORMED NAME: Sports Asylum, Inc. DATE OF NAME CHANGE: 20140324 FORMER COMPANY: FORMER CONFORMED NAME: Plandel Resources, Inc. DATE OF NAME CHANGE: 20100608 10-Q 1 cmxc_10q.htm QUARTERLY REPORT 10Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

[X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended November 30, 2018

[ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Commission File Number: 000-54500

Cell MedX Corp.

(Exact name of registrant as specified in its charter)


Nevada		38-3939625
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification No.)

123 W. Nye Ln, Suite 446

Carson City, NV

89706

(Address of principal executive offices)

(Zip code)

(844) 238-2692

(Registrant’s telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or such shorter period that the registrant was required to submit and post such files). Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer [ ]		Accelerated filer [ ]
Non-accelerated filer [ ]		Smaller Reporting Company [X]
		Emerging Growth Company [ ]

Indicate by check mark whether the registrant is a shell company (as defined in rule 12b-2 of the Exchange Act.) Yes [ ] No [X]

The number of shares of the Registrant’s common stock, par value $.001 per share, outstanding as of January 14, 2019 was 44,282,749.

CONTENTS


PART I - FINANCIAL INFORMATION	1
Item 1. Financial Statements	1
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations	9
Item 3. Quantitative and Qualitative Disclosure about Market Risk	14
Item 4. Controls and Procedures	14
PART II - OTHER INFORMATION	16
Item 1. Legal Proceedings	16
Item 1A. Risk Factors	16
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	20
Item 3. Defaults upon Senior Securities	20
Item 4. Mine Safety Disclosures	20
Item 5. Other Information	20
Item 6. Exhibits	20
SIGNATURES	24

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

CELL MEDX CORP.

CONSOLIDATED BALANCE SHEETS

(EXPRESSED IN US DOLLARS)


	November 30, 2018		May 31, 2018
	(Unaudited)
ASSETS

Current assets
Cash	$	24,377	$	8,200
Inventory		59,787		10,793
Other current assets		9,216		26,266
Total current assets		93,380		45,259

Equipment		1,772		-
Total assets	$	95,152	$	45,259


LIABILITIES AND STOCKHOLDERS' DEFICIT
Accounts payable	$	668,980	$	594,716
Accrued liabilities		7,493		20,600
Due to related parties		360,085		334,317
Notes and advances payable		194,371		117,459
Unearned revenue		301,277		51,585
Total liabilities		1,532,206		1,118,677

STOCKHOLDERS' DEFICIT
Common stock, $0.001 par value, 300,000,000 shares authorized; 44,282,749 shares issued and outstanding at November 30, 2018 and May 31, 2018, respectively		44,283		44,283
Additional paid-in capital		4,916,201		4,916,201
Reserves		14,400		14,400
Accumulated deficit		(6,421,823)		(6,050,841)
Accumulated other comprehensive income		9,885		2,539
Total stockholders' deficit		(1,437,054)		(1,073,418)
Total liabilities and stockholders’ deficit	$	95,152	$	45,259

The accompanying notes are an integral part of these unaudited interim consolidated financial statements.

CELL MEDX CORP.

CONSOLIDATED STATEMENTS OF OPERATIONS

(EXPRESSED IN US DOLLARS)

(Unaudited)


	Three Months Ended November 30,				Six Months Ended November 30,
	2018		2017		2018		2017

Operating expenses
Amortization	$	110	$	38,434	$	110	$	77,557
Consulting fees		66,678		61,422		130,638		644,881
General and administrative expenses		24,448		33,586		52,077		88,061
Research and development costs		33,633		41,491		183,367		88,994
Stock-based compensation		-		6,130		-		106,931
Total operating expenses		124,869		181,063		366,192		1,006,424

Other items
Interest		(2,648)		(327)		(4,790)		(8,241)
Net loss		(127,517)		(181,390)		(370,982)		(1,014,665)

Unrealized foreign exchange translation gain (loss)		6,477		1,464		7,346		(170)
Comprehensive loss	$	(121,040)	$	(179,926)	$	(363,636)	$	(1,014,835)

Net loss per common share
Basic and diluted	$	(0.00)	$	(0.00)	$	(0.01)	$	(0.02)

Weighted average number of shares outstanding
Basic and diluted		44,282,749		41,997,595		44,282,749		41,116,310

The accompanying notes are an integral part of these unaudited interim consolidated financial statements.

CELL MEDX CORP.

CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT

(EXPRESSED IN US DOLLARS)

(Unaudited)


				Additional						Accumulated Other
	Common Stock			Paid-in				Deficit		Comprehensive
	Shares	Amount		Capital		Reserves		Accumulated		Income		Total

Balance - May 31, 2017	40,244,605	$	40,245	$	3,294,224	$	-	$	(4,504,043)	$	247	$	(1,169,327)

Stock-based compensation	-		-		106,931		-		-		-		106,931
Options issued for consulting fees	-		-		522,407		-		-		-		522,407
Shares issued for cash	1,480,000		1,480		368,520		-		-		-		370,000
Shares issued for debt	2,318,144		2,318		577,218		-		-		-		579,536
Net loss for the six months ended November 30, 2017	-		-		-		-		(1,014,665)		-		(1,014,665)
Translation to reporting currency	-		-		-		-		-		(170)		(170)

Balance - November 30, 2017	44,042,749		44,043		4,869,300		-		(5,518,708)		77		(605,288)

Stock-based compensation	-		-		1,541		-		-		-		1,541
Units issued on conversion of deposits	240,000		240		45,360		14,400		-		-		60,000
Net loss for the six months ended May 31, 2018	-		-		-		-		(532,133)		-		(532,133)
Translation to reporting currency	-		-		-		-		-		2,462		2,462
							-
Balance - May 31, 2018	44,282,749		44,283		4,916,201		14,400		(6,050,841)		2,539		(1,073,418)

Net loss for the six months ended November 30, 2018	-		-		-		-		(370,982)		-		(370,982)
Translation to reporting currency	-		-		-		-		-		7,346		7,346

Balance - November 30, 2018	44,282,749	$	44,283	$	4,916,201	$	14,400	$	(6,421,823)	$	9,885	$	(1,437,054)

The accompanying notes are an integral part of these unaudited interim consolidated financial statements.

CELL MEDX CORP.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(EXPRESSED IN US DOLLARS)

(Unaudited)


	Six Months Ended November 30,
	2018		2017

Cash flows used in operating activities
Net loss	$	(370,982)	$	(1,014,665)
Adjustments to reconcile net loss to net cash used in operating activities
Accrued interest on notes payable		4,790		8,241
Amortization		110		77,557
Consulting fees - non-cash		-		522,407
Non-cash financing fees		387		-
Unrealized foreign exchange		(2,788)		5,127
Stock-based compensation		-		106,931
Changes in operating assets and liabilities
Inventory		(50,072)		(21,133)
Other current assets		16,823		(99,028)
Accounts payable		75,053		66,244
Accrued liabilities		(13,107)		(74,719)
Unearned revenue		250,000		59,588
Due to related parties		26,352		30,246
Net cash flows used in operating activities		(63,434)		(333,204)

Cash flows used in investing activities
Acquisition of equipment		(1,915)		-
Net cash used in investing activities		(1,915)		-

Cash flows from financing activities
Advances payable		28,871		(22,704)
Proceeds from notes payable		47,004		25,318
Proceeds from subscription to shares		-		370,000
Net cash provided by financing activities		75,875		372,614

Effects of foreign currency exchange on cash		5,651		1,464
Increase in cash		16,177		40,874
Cash, beginning		8,200		67,494
Cash, ending	$	24,377	$	108,368

Non-cash financing transactions:
Settlement of debt with shares	$	-	$	579,536

The accompanying notes are an integral part of these unaudited interim consolidated financial statements.

CELL MEDX CORP.

NOTES TO THE UNAUDITED INTERIM

CONSOLIDATED CONDENSED FINANCIAL STATEMENTS

NOVEMBER 30, 2018

NOTE 1 - ORGANIZATION AND NATURE OF OPERATIONS

Cell MedX Corp. (the “Company”) was incorporated under the laws of the State of Nevada. On April 26, 2016, the Company formed a subsidiary, Cell MedX (Canada) Corp. (“Cell MedX Canada”) under the laws of the province of British Columbia.

The Company is in an early development stage focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness and alleviate complications associated with medical conditions including, but not limited to, diabetes, Parkinson’s disease, and high blood pressure.

Unaudited Interim Financial Statements

The unaudited interim consolidated financial statements of the Company have been prepared in accordance with United States generally accepted accounting principles (“GAAP”) for interim financial information and the rules and regulations of the Securities and Exchange Commission (the “SEC”). They do not include all information and footnotes required by GAAP for complete financial statements. Except as disclosed herein, there have been no material changes in the information disclosed in the notes to the consolidated financial statements for the year ended May 31, 2018, included in the Company’s Annual Report on Form 10-K, filed with the SEC. The interim unaudited consolidated financial statements should be read in conjunction with those audited consolidated financial statements included in Form 10-K. In the opinion of management, all adjustments considered necessary for fair presentation, consisting solely of normal recurring adjustments, have been made. Operating results for the three and six months ended November 30, 2018, are not necessarily indicative of the results that may be expected for the year ending May 31, 2019.

Going concern

The accompanying unaudited interim consolidated condensed financial statements have been prepared assuming the Company will continue as a going concern. As of November 30, 2018, the Company has not achieved profitable operations and has accumulated a deficit of $6,421,823. Continuation as a going concern is dependent upon the ability of the Company to obtain the necessary financing to meet obligations and pay its liabilities arising from normal business operations when they come due and ultimately upon its ability to achieve profitable operations. The outcome of these matters cannot be predicted with any certainty at this time and raises substantial doubt that the Company will be able to continue as a going concern. These financial statements do not include any adjustments to the amounts and classification of assets and liabilities that may be necessary should the Company be unable to continue as a going concern. Management intends to obtain additional funding by borrowing funds from its directors and officers, issuing promissory notes and/or a private placement of common stock.

NOTE 2 - RELATED PARTY TRANSACTIONS

Amounts due to related parties, other than notes payable to related parties (Note 7) at November 30, 2018 and May 31, 2018:


	November 30, 2018		May 31, 2018
Due to the former Chief Executive Officer (“CEO”) and director	$	52,626	$	54,275
Due to a director, CEO and President		54,000		32,400
Due to the Chief Financial Officer (“CFO”)		30,735		20,790
Due to the Vice President (“VP”), Technology and Operations		54,895		59,035
Due to the former Chief Medical Officer		81,059		81,059
Due to the former VP, Corporate Strategy		86,770		86,758
Due to related parties	$	360,085	$	334,317

These amounts are unsecured, due on demand and bear no interest.

During the six-month periods ended November 30, 2018 and 2017, the Company had the following transactions with related parties:


	November 30, 2018		November 30, 2017
Management fees incurred to the CEO	$	21,600	$	21,600
Management fees incurred to the CFO		6,000		6,000
Stock-based compensation incurred to the CFO		--		89,556
Consulting fees incurred to the VP, Technology and Operations		25,638		23,475
Stock-based compensation incurred to the Former Chief Medical Officer		--		17,375
Accrued interest expense incurred to the Company’s shareholder (Note 7)		4,294		3,170
Total transactions with related parties	$	57,532	$	161,176

NOTE 3 - INVENTORY

As at November 30, 2018, the inventory consisted of supplies held for resale valued at $13,694 (May 31, 2018 - $10,793) and work in progress, which was associated with manufacturing of eBalance devices, valued at $46,093 (May 31, 2018 - $Nil).

NOTE 4 - OTHER CURRENT ASSETS

As at November 30, 2018, other current assets consisted of $2,572 in prepaid expenses (May 31, 2018 - $23,915) and $6,644 in receivables associated with GST Cell MedX Canada paid on the taxable supplies (May 31, 2018 - $2,351).

NOTE 5 - EQUIPMENT

Amortization schedule for the equipment at November 30, 2018 and May 31, 2018:


	November 30, 2018		May 31, 2018
Book value, beginning of the period	$	--	$	193,571
Changes during the period		1,915		(193,571)
Amortization		(110)		--
Foreign exchange		(33)		--
Book value, end of the period	$	1,772	$	--

NOTE 6 - UNEARNED REVENUE

As at May 31, 2018, the Company recorded $301,277 (May 31, 2018 - $51,585) in unearned revenue for deposits, of which $250,000 represented a refundable deposit for exclusive worldwide distribution rights the Company received from an arms-length party under the terms of the letter of intent (the “LOI”) the Company signed on September 10, 2018.

NOTE 7 - NOTES AND ADVANCES PAYABLE

The tables below summarize the short-term loans and advances outstanding as at November 30, 2018 and May 31, 2018:


As at November 30, 2018
Principal Outstanding		Interest Rate per Annum		Accrued Interest		Total Book Value
$	29,457	6%	Non-convertible	$	716	$	30,173
	115,964	0%-12%	Former related party⁽¹⁾		8,184		124,148
	40,050	0%	Advances⁽²⁾		--		40,050
$	185,471			$	8,900	$	194,371


As at May 31, 2018
Principal Outstanding		Interest Rate per Annum		Accrued Interest		Total Book Value
$	6,000	6%	Non-convertible	$	225	$	6,225
	95,570	6%-12%	Former related party		4,066		99,636
	11,598	0%	Advances		--		11,598
$	113,168			$	4,291	$	117,459

(1) Former Related Party Loans Payable

During the six-month period ended November 30, 2018, the Company entered into three separate unsecure loan agreements with Mr. Richard Jeffs, our shareholder, for a total of $23,029 (CAD$30,000) (May 31, 2018 - $34,840):


Date	Principal (CAD$)	Interest Rate	Additional Terms	Accrued Interest (CAD$)	Total Book Value (CAD$)
June 7, 2018	$10,500	12%	Convertible into units of the Company’s common stock at $0.10 per unit. Includes CAD$500 finance fee, added to principal. Payable on demand.	$622	$11,122
July 3, 2018	$10,000	0%	Short-term loan payable within 14 days after grant. As at November 30, 2018, the loan has not been repaid and therefore was payable on demand.	--	10,000
August 1, 2018	$10,000	12%	Convertible into units of the Company’s common stock on the terms and at a price of the private placement offering open at the time of conversion. Payable on demand.	404	10,404
	$30,500			$1,026	$31,526

(2) Advances Payable

During the six-month period ended November 30, 2018, the Company borrowed $28,871 from unrelated parties. The advances are non-interest bearing, unsecured and payable on demand.

Interest Expense

During the six-month period ended November 30, 2018, the Company recorded $4,790 (2017 - $8,241) in interest expense associated with its liabilities under the notes and advances payable.

NOTE 8 - SHARE CAPITAL

Options

The changes in the number of stock options outstanding during the six-month period ended November 30, 2018, and for the year ended May 31, 2018 are as follows:


	Six months ended November 30, 2018			Year ended May 31, 2018
	Number of options	Weighted average exercise price		Number of options	Weighted average exercise price
Options outstanding, beginning	9,450,000	$	0.35	7,550,000	$	0.35
Options granted	--	$	n/a	2,050,000	$	0.35
Options expired	--	$	n/a	(150,000)	$	0.20
Options cancelled	(2,400,000)	$	0.67	--	$	n/a
Options outstanding, ending	7,050,000	$	0.24	9,450,000	$	0.35

Details of options outstanding and exercisable as at November 30, 2018, are as follows:


Exercise price	Grant date	Number of options Outstanding and exercisable
$0.05	November 25, 2014	2,500,000
$0.35	August 5, 2015	2,500,000
$0.35	August 24, 2017	2,050,000
		7,050,000

At November 30, 2018, the weighted average remaining contractual life of the stock options outstanding was 2.45 years.

Warrants

The changes in the number of warrants outstanding during the six-month period ended November 30, 2018, and for the year ended May 31, 2018 are as follows:


	Six months ended November 30, 2018	Year ended May 31, 2018
Warrants outstanding, beginning	12,814,605	11,094,605
Warrants issued	-	1,720,000
Warrants outstanding, ending	12,814,605	12,814,605

Details of warrants outstanding as at November 30, 2018, are as follows:


Exercise price	Grant Date	Number of warrants exercisable
$0.40 during the period from March 3, 2018 to March 3, 2019 $0.60 during the period from March 3, 2019 to March 3, 2020 $0.75 during the period from March 3, 2020 to March 3, 2021	March 3, 2016	2,000,000
$1.00 during the period from October 12, 2018 to October 12, 2019 $1.25 during the period from October 12, 2019 to October 12, 2020 $1.50 during the period from October 12, 2020 to October 12, 2021	October 12, 2016	9,094,605
$1.00 during the period from October 12, 2018 to October 12, 2019 $1.50 during the period from October 12, 2019 to October 12, 2020	October 12, 2017	1,480,000
$0.50 up to February 7, 2019 $1.00 during the period from February 7, 2019 to February 7, 2020 $1.50 during the period from February 7, 2020 to February 7, 2021	February 7, 2018	240,000
		12,814,605

At November 30, 2018, the weighted average life and price of the warrants was 2.64 years and $0.83, respectively.

NOTE 9 - SUBSEQUENT EVENT

Subsequent to November 30, 2018, the Company entered into a credit line agreement (the “Agreement”) with Mr. Jeffs (the “Lender”), for an unsecured line of credit of up to $250,000 (the “Credit Line”) of which $100,000 was advanced to the Company on December 20, 2018. The funds advanced under the Credit Line accumulate interest at a rate of 6% per annum compounded monthly.

In consideration for the Credit Line the Company issued to the Lender non-transferable share purchase warrants (the “Warrants”) to purchase up to 5,000,000 shares exercisable at $0.05 per share and expiring on December 27, 2021. The Warrants vest at a rate of 20 warrants for every $1 drawn on the Credit Line, with 2,000,000 warrants having vested on the grant date.

In addition, in recognition of $124,148 previously advanced by the Lender, the Company issued to the Lender non-transferable share purchase warrants (the “Additional Warrants”) to purchase up to 2,482,960 shares exercisable at $0.05 per share and expiring on December 27, 2021. The Additional Warrants vested at the time of grant.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion of our financial condition and results of operations should be read in conjunction with our unaudited interim consolidated financial statements, the notes to those financial statements and other financial information appearing elsewhere in this document. In addition to historical information, the following discussion and other parts of this document contain forward-looking statements that reflect plans, estimates, intentions, expectations and beliefs. Actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those set forth in the "Risk Factors" in Part II, Item 1A of this Quarterly Report.

The discussion provided in this Quarterly Report should be read in conjunction with our Annual Report on Form 10-K for the year ended May 31, 2018, filed with the United States Securities and Exchange Commission (the “SEC”) on September 13, 2018.

Overview

We were incorporated as Plandel Resources, Inc. under the laws of the State of Nevada on March 19, 2010. On March 24, 2014, we changed our name to Sports Asylum, Inc. and on September 30, 2014, we changed our name to Cell MedX Corp. to reflect our current business direction.

On November 25, 2014, we completed the acquisition of a proprietary method for the application of bioelectric signaling to treat diabetes and related ailments (the “eBalance Technology”). With our acquisition of the eBalance Technology, we have shifted our business direction to the discovery, development, and commercialization of therapeutic and non-therapeutic products that promote general wellness and alleviate complications associated with medical conditions including, but not limited to, diabetes, Parkinson’s disease, and high blood pressure.

On April 26, 2016, we formed a subsidiary, Cell MedX (Canada) Corp., (the “Subsidiary”) under the laws of the Province of British Columbia, in anticipation of increased business activity in Canada. As of the day of this Quarterly Report on Form 10-Q, the Subsidiary is engaged in manufacturing and further development of eBalance Technology.

Recent Corporate Developments

The following corporate developments occurred during the quarter ended November 30, 2018, and up to the date of the filing of this report:

Letter of Intent for Worldwide Distribution Rights

On September 10, 2018, we entered into a non-binding letter of intent (the “LOI”) with Live Current Media, Inc. (“LIVC”), an arms-length party, for worldwide distribution rights of eBalance devices for home-based usage.

Pursuant to the LOI, we agreed to enter into negotiations with LIVC aiming at obtaining a definitive agreement within a 90-day period. LIVC advanced us $250,000 as a deposit for exclusive worldwide distribution rights (the “Deposit”). If we do not reach a definitive agreement within contemplated 90 days of the execution of the LOI, the deposit will be treated as a non-interest bearing advance payable on demand.

On December 10, 2018, we extended the LOI for an additional 90-day period on the same terms as previously agreed upon.

Royalty Agreements

On September 6, 2018, we entered into an intellectual property royalty agreement (the “IP Royalty Agreement”), whereby we agreed to acquire certain additional developments and improvements for our eBalance devices that were developed by the IP Vendor in exchange for a perpetual royalty of USD$350 or CAD$350 for each device sold, distributed or licensed whether through a distributor, sales representative or directly by us. We agreed that the currency of the royalty payments would depend on the currency the revenue is generated in.

On September 6, 2018, we entered into an additional royalty agreement with Richard Jeffs, our shareholder (the “Royalty Agreement”). Under the Royalty Agreement, we agreed to pay Mr. Jeffs, in perpetuity, a 10% royalty on the revenue we receive from any distributors or end-users introduced to us by Mr. Jeffs.

Update on the Current Status of eBalance Devices

At the beginning of December 2018, we completed manufacturing of our first 100 Canadian-built eBalance devices. Upon receiving our Certificate of Conformity from LabTest Certification Inc., qualifying the eBalance devices as Class A (professional use) and Class B (in-home use), we collaborated with our production facility operated by NDS Electronic Solutions Inc. (“NDS”) in order to manufacture the eBalance devices. The new Canadian-built eBalance devices are manufactured in accordance with the design specifications and stringent standards imposed by the Company. The eBalance devices were certified to CSA, CE and UL standards for electrical safety and emission standards, and are eligible to bear the LabTest Certification Mark with adjacent indicators “C” and “US”.

The Company is expecting that majority of the eBalance devices manufactured in December will be used for promotional and introductory material. However, the Company is also expecting to start its commercial activity in January of 2019.

Credit Line Agreement

On December 27, 2018, we entered into an agreement with Mr. Richard Jeffs (the “Lender”), the Company’s shareholder (the “Agreement”), for an unsecured line of credit of up to $250,000 (the “Credit Line”) of which $100,000 was advanced to the Company on December 20, 2018.

Under the Agreement, we may borrow against the Credit Line and repay any portion of the amount borrowed at any time. The funds advanced under the Credit Line accumulate interest at a rate of 6% per annum. In consideration for the Credit Line, we issued to the Lender non-transferable share purchase warrants (the “Warrants”) to purchase up to 5,000,000 shares of our common stock exercisable at $0.05 per share and expiring on December 27, 2021. The Warrants vest at a rate of 20 warrants for every $1 drawn on the Credit Line, with 2,000,000 warrants having vested on the grant date of the Warrants on account of $100,000 advance noted above.

In addition, in recognition of $124,148 previously advanced by the Lender, we issued to the Lender non-transferable share purchase warrants (the “Additional Warrants”) to purchase up to 2,482,960 shares exercisable at $0.05 per share and expiring on December 27, 2021. The Additional Warrants vested at the time of grant.

We are planning to use the funds available under the Credit Line for working capital and to increase the current inventory of eBalance devices to facilitate our move toward commercialization.

Results of Operations for the Three and Six Months Ended November 30, 2018, and 2017

Our operating results for the three and six months ended November 30, 2018, and 2017, and the changes in the operating results between those periods are summarized in the table below.


	Three Months Ended					Six Months Ended
	November 30, 2018		November 30, 2017		Percentage Increase/ (Decrease)	November 30, 2018		November 30, 2017		Percentage Increase/ (Decrease)
Operating expenses
Amortization		110		38,434	(99.7)%		110		77,557	(99.9)%
Consulting fees		66,678		61,422	8.6%		130,638		644,881	(79.7)%
General and administrative expenses		24,448		33,586	(27.2)%		52,077		88,061	(40.9)%
Research and development costs		33,633		41,491	(18.9)%		183,367		88,994	106.0%
Stock-based compensation		-		6,130	(100.0)%		-		106,931	(100)%
Total operating expenses		124,869		181,063	(31.0)%		366,192		1,006,424	(63.6)%
Interest		2,648		327	709.8%		4,790		8,241	(41.9)%
Net loss	$	127,517	$	181,390	(29.7)%	$	370,982	$	1,014,665	(63.4)%

Revenues

We did not generate any revenue during the three and six months ended November 30, 2018, and 2017. Due to the current concentration on research and development of our eBalance Technology and devices based on this technology, and to a small market share, we do not expect to have significant operating revenue in the near future.

Operating Expenses

During the three-month period ended November 30, 2018, our operating expenses decreased by 31%, or $56,194 from $181,063 incurred during the three months ended November 30, 2017, to $124,869 incurred during the three months ended November 30, 2018. The decrease was mainly associated with a $38,324 reduction in our amortization expense, which decreased from $38,434 at November 30, 2017, to $110 at November 30, 2018; the decrease resulted from us fully expensing our equipment at May 31, 2018. In addition to the reduced amortization, our research and development and general and administrative fees decreased by $7,858 and $9,138, respectively, and our stock-based compensation decreased by $6,130. These reductions were in part offset by increases to our consulting fees, which increased by $5,256, from $61,422 at November 30, 2017, to $66,678 at November 30, 2018.

During the six-month period ended November 30, 2018, our operating expenses decreased by 63.6% from $1,006,424 incurred during the six months ended November 30, 2017, to $366,192 incurred during the six months ended November 30, 2018. The most significant changes were as follows:

During the six-month period ended November 30, 2018, our consulting fees decreased by $514,243, from $644,881 we incurred during the six-month period ended November 30, 2017, to $130,638 we incurred during the six months ended November 30, 2018. Larger consulting fees during the six-month period ended November 30, 2017, were associated with a fair market value of the options to acquire up to 1,750,000 shares of our common stock we granted to our consultants for business development services. We did not grant any stock options to consultants during the six-month period ended November 30, 2018.

Our research and development fees for the six-month period ended November 30, 2018, increased by $94,373, from $88,994 we incurred during the six-month period ended November 30, 2017, to $183,367 we incurred during the six months ended November 30, 2018. The higher research and development fees during the six-month period ended November 30, 2018, resulted mainly from $140,460 (CAD$185,000) we incurred to Western Robotics Ltd., whom we engaged to assist us with enhancement and further re-designing of our eBalance Pro wellness devices.

Our stock-based compensation for the six-month period ended November 30, 2018, decreased by $106,931, as we did not have any transactions that would have resulted in equity compensation. During the comparative six-month period ended November 30, 2017, our stock-based compensation was $106,931 and included $89,556 in fair market value of the options to acquire up to 300,000 shares of our common stock we granted to Ms. Silina pursuant to the stock option agreement with her, and $17,375 in fair market value of the options to acquire up to 2,400,000 shares of our common stock we granted to Dr. Sanderson, our former Chief Medical Officer.

Our general and administrative fees for the six-month period ended November 30, 2018, decreased by $35,984, or 40.9%, from $88,061 we incurred during the six-month period ended November 30, 2017, to $52,077 we incurred during the six months ended November 30, 2018. The largest factor that contributed to this change was associated with fluctuations in foreign exchange rates, which resulted in $1,257 loss we recorded during the six-month period ended November 30, 2018, as compared to $18,622 loss we recorded during the six-month period ended November 30, 2017. Other factors that affected our general and administrative fees were professional fees of $182 (2017 - $9,971), filing and regulatory fees of $13,237 (2017 - $12,788), office expenses of $2,809 (2017 - $5,537), accounting and audit fees of $770 (2017 - $4,250), and travel and entertainment expenses of $3,518 (2017 - $6,313).

Our amortization expenses, decreased by $77,447, from $77,557 we recorded for the six-month period ended November 30, 2017, to $110 we recorded for the six-month period ended November 30, 2018. The decrease was associated with our decision to fully expense the equipment we acquired in the prior years, as the Company did not expect to receive a future benefit from the equipment.

Other Items

During the six-month period ended November 30, 2018, we accrued $4,790 (2017 - $8,241) in interest associated with the outstanding notes payable. Of this interest, $4,294 (2017 - $3,170) was accrued on the notes payable we issued to Mr. Jeffs, our shareholder.

Liquidity and Capital Resources

Working Capital


	As at November 30, 2018		As at May 31, 2018		Percentage Change
Current assets	$	93,380	$	45,259	106.3%
Current liabilities		1,532,206		1,118,677	37.0%
Working capital deficit	$	(1,438,826)	$	(1,073,418)	34.0%

As of November 30, 2018, we had a cash balance of $24,377, a working capital deficit of $1,438,826 and cash flows used in operations of $63,434 for the period then ended. During the six-month period ended November 30, 2018, we funded our operations with $23,029 (CAD$30,000) we received from Mr. Jeffs, our shareholder, $23,975 (CAD$31,200) we received from an unrelated lender and $28,871 we borrowed from unrelated parties as short-term, non-interest bearing advances.

We did not generate sufficient cash flows from our operating activities to satisfy our cash requirements for the period ended November 30, 2018. The amount of cash we have generated from our operations to date is significantly less than our current debt obligations. There is no assurance that we will be able to generate sufficient cash from our operations to repay the amounts owing under these notes and advances payable, or to service our other debt obligations. If we are unable to generate sufficient cash flow from our operations to repay the amounts owing when due, we may be required to raise additional financing from other sources. The outcome of these matters cannot be predicted with any certainty at this time and raises substantial doubt that we will be able to continue as a going concern.

Cash Flows


	Six months ended November 30,
	2018		2017
Cash flows used in operating activities	$	(63,434)	$	(333,204)
Cash flows used in investing activities		(1,915)		-
Cash flows provided by financing activities		75,875		372,614
Effects of foreign currency exchange on cash		5,651		1,464
Net increase in cash during the period	$	16,177	$	40,874

Net Cash Used in Operating Activities

Net cash used in operating activities during the six months ended November 30, 2018, was $63,434. This cash was primarily used to cover our cash operating expenses of $368,483, to increase our inventory by $3,240, work in progress by $46,832, and to decrease our accrued liabilities by $13,107. These uses of cash were offset by increases in our accounts payable and amounts due to related parties of $75,053 and $26,352, respectively, by $16,823 increase to our current assets and $250,000 increase in unearned revenue associated with a deposit we received under the LOI with Live Current Media, Inc.

Net cash used in operating activities during the six months ended November 30, 2017, was $333,204. This cash was primarily used to cover our cash operating expenses of $294,402, to increase our inventory by $6,017, work in progress recorded as part of inventory by $15,116, and current assets by $99,028. The cash used for current assets included $97,010 (CAD$125,000) we paid under our Development Agreement to enhance our eBalance Pro Wellness device. In addition, we used our cash to reduce our accrued liabilities by $74,719. These uses of cash were offset by increases in our accounts payable and amounts due to related parties of $66,244 and $30,246, and $59,588 in unearned revenue associated with a deposit we received on eBalance distribution contract.

Non-cash transactions

During the six months ended November 30, 2018, our net loss was affected by the following expenses that did not have any impact on cash used in operations:

$4,790 in interest we accrued on the outstanding notes payable. Of this interest, $4,294 was accrued on the notes payable we issued to Mr. Jeffs, our shareholder;

$387 in financing fees associated with notes payable we issued to Mr. Jeffs;

$110 in amortization on new equipment we acquired for our manufacturing operations, and

$2,788 in unrealized foreign exchange, which resulted from fluctuations of the Canadian dollar and European Euro-denominated transactions.

During the six months ended November 30, 2017, our net loss was affected by the following expenses that did not have any impact on cash used in operations:

$106,931 in stock-based compensation, of which $89,556 was associated with the fair value of the options to purchase up to 300,000 shares of our common stock we granted to Ms. Silina, our CFO, as compensation for her services; and $17,375 was associated with the fair value of the options to purchase up to 2,400,000 shares of our common stock we granted to Dr. Sanderson, our Chief Medical Officer;

$522,407 in fair value of the option to acquire up to 1,750,000 shares our common stock we issued for consulting services;

$8,241 in interest we accrued on the outstanding notes payable. Of this interest, $3,170 was accrued on the notes payable we issued to Mr. Jeffs, our shareholder;

$77,557 in amortization expense we recorded on the equipment we use in our research of the eBalance Technology; and

$5,127 in unrealized foreign exchange, which resulted from fluctuations of the Canadian dollar and European Euro-denominated transactions.

Net Cash Provided by Financing Activities

During the six months ended November 30, 2018, we borrowed a total of $23,029 (CAD$30,000) from our shareholder. Of this amount CAD$20,000 in principal bear interest at 12% per annum, compounded monthly, are unsecured and payable on demand; and CAD$10,000 was advanced as a non-interest bearing short-term loan, which was payable within 14 days from the grant. We have not repaid this loan when due, and therefore it is payable on demand. In addition, we borrowed $23,975 (CAD$31,200) from an unrelated party. The loan bears interest at 6% per annum and is compounded monthly. During the same period, we borrowed a total of $28,871 from unrelated parties under non-interest bearing advances which are payable on demand.

During the six-month period ended November 30, 2017, we borrowed a total of $19,318 (CAD$25,000) from our shareholder and $6,000 from an unrelated party. The loans are unsecured, payable on demand and bear interest at 6% per annum, compounded monthly. In addition to the loans, we received $370,000 from subscriptions to the units of our common stock under the Offering, which we closed on October 12, 2017. During the same period we repaid net of $22,704 in non-interest bearing advances with an unrelated party.

On September 15, 2017, we received a notice from Mr. Jeffs that he had assigned the rights to $7,984 due to him under the demand notes payable and $54,516 due to him under the Term Loan to two unaffiliated parties. The assignees notified the Company of their intention to convert the debt acquired by them from Mr. Jeffs into the shares of the Company’s common stock as part of the proposed debt restructuring initiative (the “Debt Restructuring”), which we completed on October 12, 2017.

Net Cash Used in Investing Activities

During the six months ended November 30, 2018, we spent $1,915 acquiring equipment for the manufacturing of our eBalance devices. We did not have any investing activities during the six months ended November 30, 2017.

Going Concern

The notes to our unaudited interim consolidated financial statements as at November 30, 2018, disclose our uncertain ability to continue as a going concern. Our current business operations are in an early development stage, and as such, we were able to generate only minimal revenue from the operations. Our research and development plans, as well as our commercialization efforts of the eBalance devices in the near future, will require large capital expenditures, which we are planning to mitigate through equity or debt financing, or by requiring upfront deposits from our potential distributors, once we begin commercial production of our eBalance devices.

We have accumulated a deficit of $6,421,823 since inception, and increased sales will be required to fund and support our operations. Our continuation as a going concern depends upon the continued financial support of our shareholders, our ability to obtain necessary debt or equity financing to continue operations, and the attainment of profitable operations. Our audited consolidated financial statements do not give effect to any adjustments that would be necessary should we be unable to continue as a going concern and therefore be required to realize our assets and discharge our liabilities in other than the normal course of business and at amounts different from those reflected in our financial statements.

Off-Balance Sheet Arrangements

None.

Critical Accounting Policies

An appreciation of our critical accounting policies is necessary to understand our financial results. These policies may require management to make difficult and subjective judgments regarding uncertainties, and as a result, such estimates may significantly impact our financial results. The precision of these estimates and the likelihood of future changes depend on a number of underlying variables and a range of possible outcomes. We have applied our critical accounting policies and estimation methods consistently.

Changes in and Disagreements with Accountants on Accounting Procedures and Financial Disclosure

None.

Item 3. Quantitative and Qualitative Disclosure about Market Risk

None

Item 4. Controls and Procedures

Our management is responsible for establishing and maintaining a system of disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)). These controls and procedures are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company's management, including its principal executive officer or officers and principal financial officer or officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

An evaluation was conducted under the supervision and with the participation of our management of the effectiveness of the design and operation of our disclosure controls and procedures as of November 30, 2018. Based on that evaluation, our management concluded that our disclosure controls and procedures were not effective in recording, processing, summarizing and reporting information required to be disclosed within the time periods specified in Securities and Exchange Commission’s rules and forms due to lack of segregation of duties.

During the quarter ended November 30, 2018, there were no changes in our internal controls over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

None.

Item 1A. Risk Factors

There is a high degree of risk associated with investing in our securities. Prospective investors should carefully read this Quarterly Report on Form 10-Q and consider the following risk factors when deciding whether to purchase our securities.

The risk factors outlined below are some of the known, substantial, material and potential risks that could adversely affect our business, financial condition, operating results, and common share value. We cannot assure that we will successfully address these or any unknown risks and a failure to do so can have a negative impact on your investment. We may encounter risks in addition to those described below. Additional risks and uncertainties not currently known to us, or that we currently deem to be immaterial may also impair or adversely affect our business, financial condition or results of operation.

Risks Associated with our Company and our Industry

We operate in a highly competitive market. We face competition from large, well established medical device manufacturers and pharmaceutical companies in the market for treating and managing diabetes and related ailments. Many of these companies are very well accepted by health practitioners and have significant resources, and we may not be able to compete effectively.

The market for devices and therapies for treating and managing diabetes and related ailments is intensely competitive, subject to rapid change and significantly affected by new product introductions. We compete indirectly with large pharmaceutical and medical device companies, such as Bayer Corp., Becton Dickinson Corp., LifeScan Inc., a division of Johnson & Johnson, MediSense Inc., and TheraSense Inc. These competitors’ products are based on traditional healthcare model and are well accepted by health practitioners and patients. If these companies decide to penetrate our target market they could threaten our position in the market.

We are subject to numerous governmental regulations which can increase our costs of developing our eBalance Technology and products based on this technology.

Our products may be subject to rigorous regulation by the FDA, Health Canada, and numerous international, supranational, federal, and state authorities. The process of obtaining regulatory approvals to market a medical device can be costly and time-consuming, and approvals might not be granted for future products, or additional indications or uses of existing products, on a timely basis, if at all. Delays in the receipt of, or failure to obtain approvals for, our products, or new indications and uses, could result in delayed realization of product revenues, reduction in revenues, and substantial additional costs. In addition, we can give no assurance that we will remain in compliance with applicable FDA, Health Canada, and other regulatory requirements once we receive an approval or marketing authorization for a product. These requirements include, among other things, regulations regarding manufacturing practices, product labeling, and advertising and post-marketing reporting, including adverse event reports and field alerts due to manufacturing quality concerns.

Changes in the health care regulatory environment may adversely affect our business.

A number of the provisions of the U.S. Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010 and its amendments changed access to health care products and services and established new fees for the medical device industry. Future rulemaking could increase rebates, reduce prices or the rate of price increases for health care products and services, or require additional reporting and disclosure. We cannot predict the timing or impact of any future rulemaking.

Competitors' intellectual property may prevent us from selling our products or have a material adverse effect on our future profitability and financial condition.

Competitors may claim that our Technology infringes upon their intellectual property. Resolving an intellectual property infringement claim can be costly and time-consuming and may require us to enter into license agreements. We cannot guarantee that we would be able to obtain license agreements on commercially reasonable terms. A successful claim of patent or other intellectual property infringement could subject us to significant damages or an injunction preventing the manufacture, sale or use of our product. Any of these events could have a material adverse effect on our profitability and financial condition.

Our research and development efforts may not result in the development of commercially successful products based on our eBalance Technology, which may hinder our profitability and future growth.

Our eBalance Technology is currently in the research and development stage as are our planned products incorporating this technology. To develop commercially marketable products, we will be required to commit substantial efforts, funds, and other resources to research and development. A high rate of failure is inherent in the research and development of new products and technologies. We must make substantial ongoing expenditures without any assurance that our efforts will be commercially successful. Failure can occur at any point in the process, including after investment of significant funds. Planned products may fail to reach the market or may only have limited commercial success because of efficacy or safety concerns, failure to achieve positive clinical outcomes, inability to obtain necessary regulatory approvals, limited scope of approved uses, excessive costs to manufacture, the failure to establish or maintain intellectual property rights, or infringement of the intellectual property rights of others.

Even if we successfully develop marketable products or commercially develop our current technology, we may be quickly rendered obsolete by changing customer preferences, changing industry standards, or competitors' innovations.

Innovations may not be accepted quickly in the marketplace because of, among other things, entrenched patterns of clinical practice or uncertainty over third-party reimbursement. We cannot state with certainty when or whether we will be launching our products under development, whether we will be able to develop, license, or otherwise acquire new products, or whether any products will be commercially successful. Failure to launch successful new products or new indications for existing products may cause our products to become obsolete, causing our revenues and operating results to suffer.

New products and technological advances by our competitors may negatively affect our results of operations.

Our products face intense competition from our competitors. Competitors' products may be safer, more effective, more effectively marketed or sold, or have lower prices or superior performance features than our products. We cannot predict with certainty the timing or impact of the introduction of competitors' products.

Significant safety concerns could arise for our products, which could have a material adverse effect on our revenues and financial condition.

Healthcare products typically receive regulatory approval based on data obtained in controlled clinical trials of limited duration. Following regulatory approval, these products will be used over longer periods of time in many patients. Investigators may also conduct additional, and perhaps more extensive, studies. If new safety issues are reported, we may be required to amend the conditions of use for a product. For example, we may be required to provide additional warnings on a product's label or narrow its approved intended use, either of which could reduce the product's market acceptance. If serious safety issues arise with our product, sales of the product could be halted by us or by regulatory authorities. Safety issues affecting suppliers' or competitors' products also may reduce the market acceptance of our products.

Inability to attract and maintain key personnel may cause our business to fail.

Success depends on the acquisition of key personnel. We will have to compete with other companies both within and outside the healthcare industry to recruit and retain competent employees and consultants. If we cannot maintain qualified personnel to meet the needs of our anticipated growth, we could face material adverse effects on our business and financial condition.

To date we have generated only minimal revenues. If we cannot increase our revenues to start generating profits, our investors may lose their entire investment.

To date we have generated only minimal revenues. No profits have been made to date, and if we fail to make any, then we may fail as a business, and an investment in our common stock will be worth nothing. We have a very limited operating history and thus our progress, as well as potential future success, cannot be reasonably estimated. Success has yet to be proven, and financial losses should be expected to continue in the near future and at least until such time that we enter commercial production of devices based on the eBalance Technology, of which there is no assurance. We continue to face all the risks of a ‘start-up’ venture including unforeseen costs, expenses, problems, and management limitations and difficulties. Since inception, we have accumulated a deficit of $6,421,823 and there is no guarantee, that we may ever be able to turn a profit or locate additional opportunities, hire additional management and other personnel.

We need to acquire additional financing, or our business will fail.

We must obtain additional capital, or our business will fail. To continue development of our eBalance Technology and to complete clinical trials, we must secure more funds. Currently, we have very limited resources and have already accumulated a net loss. Financing may be subject to numerous factors including investor sentiment, acceptance of our technology and so on. We currently have no arrangements for additional financing. We may also have to borrow large sums of money that require substantial capital and interest payments.

Risks related to our stock

We expect to raise additional capital through the offering of more shares, which will result in dilution to our current shareholders.

Raising additional capital through future offerings of common stock is expected to be necessary for our Company to continue. However, there is no guarantee that we will be successful in raising additional capital. Issuance of additional stock will increase the total number of shares issued and outstanding resulting in a decrease in the percentage interest held by each of our shareholders.

There is a limited market for our common stock meaning that our shareholders may not be able to resell their shares.

Our common stock currently has a limited market which may restrict shareholders’ ability to resell their stock or use their stock as collateral. Thus, the shareholders may have to sell their shares privately which may prove very difficult. Private sales are more difficult and often give lower than anticipated prices.

Should a larger public market develop for our stock, future sales of shares may negatively affect their market price.

Even if a larger market develops, the shares may be sparsely traded and have wide share price fluctuations. Liquidity may be low despite there being a market, making it difficult to get a return on the investment. The price also depends on potential investor’s feelings regarding the results of our operations, the competition of other companies’ shares, our ability to generate future revenues, and market perception about future of microcurrent technologies.

Because our stock is a penny stock, stockholders will be more limited in their ability to sell their stock.

The SEC has adopted rules that regulate broker-dealer practices in connection with transactions in penny stocks. Penny stocks are generally equity securities with a price of less than $5.00, other than securities registered on certain national securities exchanges or quoted on the NASDAQ system, provided that current price and volume information with respect to transactions in such securities is provided by the exchange or quotation system.

Because our securities constitute "penny stocks" within the meaning of the rules, the rules apply to us and to our securities. The rules may further affect the ability of owners of shares to sell our securities in any market that might develop for them. As long as the quotation price of our common stock is less than $5.00 per share, the common stock will be subject to Rule 15g-9 under the Exchange Act. The penny stock rules require a broker-dealer, prior to a transaction in a penny stock, to deliver a standardized risk disclosure document prepared by the SEC, that:

contains a description of the nature and level of risk in the market for penny stocks in both public offerings and secondary trading;

contains a description of the broker's or dealer's duties to the customer and of the rights and remedies available to the customer with respect to a violation of such duties or other requirements of securities laws;

contains a brief, clear, narrative description of a dealer market, including bid and ask prices for penny stocks and the significance of the spread between the bid and ask price;

contains a toll-free telephone number for inquiries on disciplinary actions;

defines significant terms in the disclosure document or the conduct of trading in penny stocks; and

contains such other information and is in such form, including language, type, size, and format, as the SEC shall require by rule or regulation.

The broker-dealer also must provide, prior to effecting any transaction in a penny stock, the customer with (a) bid and offer quotations for the penny stock; (b) the compensation of the broker-dealer and its salesperson in the transaction; (c) the number of shares to which such bid and ask prices apply, or other comparable information relating to the depth and liquidity of the market for such stock; and (d) a monthly account statements showing the market value of each penny stock held in the customer's account. In addition, the penny stock rules require that, prior to a transaction in a penny stock not otherwise exempt from those rules, the broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser's written acknowledgment of the receipt of a risk disclosure statement, a written agreement to transactions involving penny stocks, and a signed and dated copy of a written suitability statement. These disclosure requirements may have the effect of reducing the trading activity in the secondary market for our stock.

We have not paid nor anticipate paying cash dividends on our common stock.

We have not declared any dividends on our common stock during the past two fiscal years or at any time in our history. The Nevada Revised Statutes (the “NRS”), provide certain limitations on our ability to declare dividends. Section 78.288 of Chapter 78 of the NRS prohibits us from declaring dividends where, after giving effect to the distribution of the dividend:

(a)

we would not be able to pay our debts as they become due in the usual course of business; or

(b)

except as may be allowed by our Articles of Incorporation, our total assets would be less than the sum of our total liabilities plus the amount that would be needed, if we were to be dissolved at the time of the distribution, to satisfy the preferential rights upon dissolution of stockholders who may have preferential rights and whose preferential rights are superior to those receiving the distribution.

We do not expect to declare any dividends in the foreseeable future as we expect to spend any funds legally available for the payment of dividends on the development of our business.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

On December 27, 2018, the Company issued to Mr. Richard Jeffs (the “Lender”) non-transferable share purchase warrants (the “Warrants”) to purchase up to 5,000,000 shares of Cell MedX’s common stock exercisable at US$0.05 per share and expiring on December 27, 2021. The Warrants were issued as consideration for the line of credit Mr. Jeffs made available to the Company under the Agreement for Credit Line, as more specifically described in the Part I, Item 2, Recent Corporate Developments section of this Quarterly Report on Form 10-Q. The Warrants vest at a rate of 20 warrants for every $1 drawn on the Credit Line, with 2,000,000 warrants having vested on the grant date of the Warrants on account of $100,000 advance issued on December 20, 2018.

In addition, in recognition of $124,148 previously advanced by the Lender in series of separate loan agreements, the Company issued to the Lender non-transferable share purchase warrants (the “Additional Warrants”) to purchase up to 2,482,960 shares exercisable at $0.05 per share and expiring on December 21, 2021. The Additional Warrants vested at the time of grant.

The Warrants and the Additional Warrants were issued to the Lender in reliance upon the exemption from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), provided by Regulation S of the Securities Act, on the basis of representations made by the Lender that he is not a "US Person" (as that term is deﬁned in Regulation S) and was not in the United States at the time the Lender acquired the Warrants. The Company did not engage in any form of “directed selling efforts” (as that term is defined in Regulation S) in connection with the offering of the Warrants to the Lender.

Item 3. Defaults upon Senior Securities

None.

Item 4. Mine Safety Disclosures

None.

Item 5. Other Information

None.

Item 6. Exhibits


Exhibit Number		Description of Document
3.1		Articles of Incorporation (2)
3.2		Articles of Merger - Sports Asylum, Inc. and Plandel Resources, Inc.(5)
3.3		Articles of Merger - Cell MedX Corp. and Sports Asylum, Inc.(5)
3.4		Bylaws (1)
4.1		Specimen Stock Certificate (1)
10.1		Letter Agreement dated August 29, 2014 among Sports Asylum, Inc., Jean Arnett, Brad Hargreaves and XC Velle Institute Inc. (4)
10.2		Consulting Agreement dated September 1, 2014 among Sports Asylum, Inc. and Jean Arnett.
10.3		Consulting Agreement dated September 1, 2014 among Sports Asylum, Inc. and Brad Hargreaves.
10.4		Technology Purchase Agreement dated October 16, 2014 among Cell MedX Corp., Jean Arnett, and Brad Hargreaves.(6)
10.5		First Amendment Agreement dated October 28, 2014 to that Technology Purchase Agreement dated October 16, 2014 among Cell MedX Corp., Jean Arnett, and Brad Hargreaves.(7)
10.6		Second Amendment Agreement dated November 13, 2014 to that Technology Purchase Agreement dated October 16, 2014 among Cell MedX Corp., Jean Arnett, and Brad Hargreaves.(8)
10.7		Non-Qualified Stock Option Agreement dated November 25, 2014 among Cell MedX Corp. and Jean Arnett.(9)


Exhibit Number		Description of Document
10.8		Non-Qualified Stock Option Agreement dated November 25, 2014 among Cell MedX Corp. and Brad Hargreaves.(9)
10.9		First Amendment to Stock-Option Agreement dated February 28, 2014 to that Non-Qualified Stock Option Agreement dated November 25, 2014 among Cell MedX Corp. and Jean Arnett.(9)
10.10		First Amendment to Stock-Option Agreement dated February 28, 2014 to that Non-Qualified Stock Option Agreement dated November 25, 2014 among Cell MedX Corp. and Brad Hargreaves. (9)
10.11		Management Consulting Agreement dated January 13, 2015 among Cell MedX Corp., and Dr. John Sanderson, MD.(10)
10.12		Stock Option Agreement dated December 12, 2014 among Cell MedX Corp. and Dr. John Sanderson, MD. (10)
10.13		Stock Option Agreement dated August 5, 2015 among Cell MedX Corp. and Frank E. McEnulty.(11)
10.14		eBalance Prototype Development Agreement dated October 1, 2015 among Cell MedX Corp., and Claudio Tassi. (12)
10.15		Non-binding Letter of Intent dated December 4, 2015 to Enter into Development Agreement and License Agreement among Cell MedX Corp., Claudio Tassi, and Bioformed Aesthetic S.L.(13)
10.16		Loan Agreement and Note Payable dated February 4, 2016, among Cell MedX Corp., and Tradex Capital Corp.
10.17		Loan Agreement and Note Payable dated March 2, 2016, among Cell MedX Corp., and Tradex Capital Corp.
10.18		Loan Agreement dated March 3, 2016 between Richard Norman Jeffs and Cell MedX Corp. (14)

10.19		Loan Agreement and Note Payable dated March 10, 2016, among Cell MedX Corp., and Tradex Capital Corp. (15)
10.20		Loan Agreement and Note Payable dated March 30, 2016, among Cell MedX Corp., and Tradex Capital Corp. (16)
10.21		Loan Agreement and Note Payable dated March 31, 2016 among Cell MedX Corp., and Richard N. Jeffs. (16)
10.22		Loan Agreement and Note Payable dated April 29, 2016, among Cell MedX Corp., and Richard N. Jeffs. (16)
10.23		Loan Agreement and Note Payable dated June 1, 2016, among Cell MedX Corp., and Tradex Capital Corp. (16)
10.24		Loan Agreement and Note Payable dated June 2, 2016, among Cell MedX Corp., and Richard N. Jeffs. (16)
10.25		Loan Agreement and Note Payable dated June 29, 2016, among Cell MedX Corp., and Tradex Capital Corp. (16)
10.26		Loan Agreement and Note Payable dated June 30, 2016, among Cell MedX Corp., and Richard N. Jeffs. (16)
10.27		Loan Agreement and Note Payable dated August 8, 2016, among Cell MedX Corp., and Richard N. Jeffs. (16)
10.28		Loan Agreement and Note Payable dated August 22, 2016, among Cell MedX Corp., and Tradex Capital Corp. (16)
10.29		Letter Agreement dated September 26, 2016, between Jean Arnett, Brad Hargreaves and Cell MedX Corp. (17)
10.30		Loan Agreement and Note Payable dated January 6, 2017, among Cell MedX Corp., and Richard N. Jeffs.(18)
10.31		Loan Agreement and Note Payable dated February 7, 2017, among Cell MedX Corp., and Richard N. Jeffs.(19)
10.32		Loan Agreement and Note Payable dated February 27, 2017, among Cell MedX Corp., and Richard N. Jeffs. (19)
10.33		Loan Agreement and Note Payable dated January 11, 2017, among Cell MedX Corp., and Perla Capital Inc. (19)
10.34		Loan Agreement and Note Payable dated January 13, 2017, among Cell MedX Corp., and Perla Capital Inc. (19)


Exhibit Number		Description of Document
10.35		Loan Agreement and Note Payable dated February 14, 2017, among Cell MedX Corp., and Perla Capital Inc. (19)
10.36		Loan Agreement and Note Payable dated March 8, 2017, among Cell MedX Corp., and Tradex Capital Corp. (19)
10.37		Loan Agreement and Note Payable dated April 18, 2017, among Cell MedX Corp., and Perla Capital Inc. (19)
10.38		Loan Agreement and Note Payable dated May 5, 2017, among Cell MedX Corp., and Tradex Capital Corp. (19)
10.39		Loan Agreement and Note Payable dated July 12, 2017, among Cell MedX Corp., and Richard N. Jeffs. (20)
10.40		Stock Option Agreement dated August 24, 2017 among Cell MedX Corp. and Yanika Silina (20)
10.41		Stock Option Agreement dated August 24, 2017 among Cell MedX Corp. and Da Costa Management Corp. (20)
10.42		Stock Option Agreement dated August 24, 2017 among Cell MedX Corp. and John Giovanni Di Cicco (20)
10.43		Product Development Agreement for eBalance dated October 16, 2017, among Cell MedX Corp. and Western Robotics Ltd.⁽²¹⁾
10.44		Management Consulting Agreement between Dr. Terrance Owen and Cell MedX Corp. dated effective as of December 1, 2017.⁽²²⁾

10.45		Loan Agreement and Note Payable dated April 5, 2018, among Cell MedX Corp., and Richard N. Jeffs.⁽²³⁾
10.46		Loan Agreement and Note Payable dated May 8, 2018, among Cell MedX Corp., and Richard N. Jeffs.⁽²³⁾
10.47		Loan Agreement and Note Payable dated June 7, 2018, among Cell MedX Corp., and Richard N. Jeffs.
10.48		Loan Agreement and Note Payable dated July 3, 2018, among Cell MedX Corp., and Richard N. Jeffs.
10.49		Loan Agreement and Note Payable dated August 1, 2018, among Cell MedX Corp., and Richard N. Jeffs.
10.50		Intellectual Property Royalty Agreement between Cell MedX Corp. and Brek Technologies Inc., dated for reference September 6, 2018.⁽²³⁾
10.51		Royalty Agreement between Cell MedX Corp. and Mr. Richard Norman Jeffs dated for reference September 6, 2018.⁽²³⁾
10.52		Letter of Intent between the Company and Live Current Media, Inc. dated for reference September 10, 2018.⁽²³⁾
10.53		Loan Agreement and Note Payable dated September 13, 2018, among Cell MedX Corp., and Tradex Capital Corp.
10.54		Credit Line Agreement dated December 27, 2018, between Richard Norman Jeffs and Cell MedX Corp.⁽²⁴⁾
14.1		Code of Ethics (3)
31.1		Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2		Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1		Certification of Principal Executive Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2		Certification of Principal Financial Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101		The following materials from this Quarterly Report on Form 10-Q for the three and six months ended November 30, 2018, and 2017 formatted in XBRL (extensible Business Reporting Language):
		(1) Consolidated Balance Sheets at November 30, 2018 (unaudited), and May 31, 2018.
		(2) Unaudited Condensed Interim Consolidated Statements of Operations for the three and six months ended November 30, 2018, and 2017.
		(3) Unaudited Condensed Interim Consolidated Statement of Stockholders’ Deficit as at November 30, 2018.
		(4) Unaudited Condensed Interim Consolidated Statements of Cash Flows for the Six-month Periods ended November 30, 2018 and 2017.

(1)

Filed as an exhibit to the Company’s Registration Statement on Form S-1 filed with SEC on July 13, 2010

(2)

Filed as an exhibit to the Company’s Amendment No. 1 to Registration Statement on Form S-1 filed with SEC on October 13, 2010

(3)

Filed as an exhibit to the Company’s Annual Report on Form 10-K filed with SEC on August 26, 2014

(4)

Filed as an exhibit to the Company’s Current Report on Form 8-K filed with SEC on September 5, 2014

(5)

Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed with the SEC on October 9, 2014

(6)

Filed as an exhibit to the Company’s Current Report on Form 8-K filed with SEC on October 17, 2014

(7)

Filed as an exhibit to the Company’s Current Report on Form 8-K filed with SEC on November 3, 2014

(8)

Filed as an exhibit to the Company’s Current Report on Form 8-K filed with SEC on November 18, 2014

(9)

Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on December 3, 2014

(10)

Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed with the SEC on January 13, 2015

(11)

Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on August 11, 2015

(12)

Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed with the SEC on January 14, 2016

(13)

Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed with the SEC on October 15, 2015

(14)

Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on March 9, 2016

(15)

Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed with the SEC on April 14, 2016

(16)

Filed as an exhibit to the Company’s Annual Report on Form 10-K filed with the SEC on September 13, 2016

(17)

Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on September 29, 2016

(18)

Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed with the SEC on April 14, 2017

(19)

Filed as an exhibit to the Company’s Annual Report on Form 10-K filed with the SEC on August 29, 2017

(20)

Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed with the SEC on October 17, 2017

(21)

Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed with the SEC on January 16, 2018

(22)

Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on December 5, 2017.

(23)

Filed as an exhibit to the Company’s Annual Report on Form 10-K filed with the SEC on September 13, 2018.

(24)

Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on December 31, 2018.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	Cell MedX Corp.

Date: January 14, 2019	By:	/s/ Frank McEnulty
		Frank McEnulty
		Chief Executive Officer and Director
		(Principal Executive Officer)

Date: January 14, 2019	By:	/s/Yanika Silina
		Yanika Silina
		Chief Financial Officer and Director
		(Principal Accounting Officer)

EX-10.53 2 cmxc_ex1053.htm LOAN AGREEMENT AND NOTE PAYABLE DATED SEPTEMBER 13, 2018 ex-10.53

LOAN AGREEMENT

September 13, 2018

Tradex Capital Corp., (the “Lender”) of 1177 W. Hastings Street, Suite 1920, Vancouver, BC V6E 2K3, advanced CAD$31,200 (the “Principal Sum”) to Cell MedX Corp. (the “Borrower”) of 123 W. Nye Ln, Suite 446, Carson City, NV 89706. The Lender advanced the funds on September 13, 2018.

The Borrower agrees to repay the Principal Sum on demand, together with interest calculated and compounded monthly at the rate of 6% per year (the “Interest”) from September 13, 2018. The Borrower is liable for repayment of the Principal Sum and accrued Interest and any costs that the Lender incurs in trying to collect the Principal Sum and the Interest.

The Borrower will evidence the debt and its repayment of the Principal Sum and the Interest with a promissory note in the attached form.


LENDER		BORROWER
Tradex Capital Corp.		Cell MedX Corp.

Per:		Per:


/s/ William Friesen		/s/ Yanika Silina
Authorized Signatory		Yanika Silina, CFO

PROMISSORY NOTE


Principal Amount: CAD$31,200	September 13, 2018

FOR VALUE RECEIVED Cell MedX Corp., (the “Borrower”) promises to pay on demand to the order of Tradex Capital Corp. (the “Lender”) the sum of $31,200 lawful money of Canada (the “Principal Sum”) together with interest on the Principal Sum from September 13, 2018 (“Effective Date”) both before and after maturity, default and judgment at the Interest Rate as defined below.

For the purposes of this promissory note, Interest Rate means 6 per cent per year. Interest at the Interest Rate must be calculated and compounded monthly not in advance from and including the Effective Date (for an effective rate of 6.2% per annum calculated monthly), and is payable together with the Principal Sum when the Principal Sum is repaid.

The Borrower may repay the Principal Sum and the Interest in whole or in part at any time.

The Borrower waives presentment, protest, notice of protest and notice of dishonour of this promissory note.

BORROWER

Cell MedX Corp.

Per:

/s/ Yanika Silina

Yanika Silina, CFO

EX-31.1 3 cmxc_ex311.htm CERTIFICATION ex-31.1

CELL MEDX CORP.

CERTIFICATIONS PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Frank McEnulty, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the period ending November 30, 2018, of Cell MedX Corp.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an Annual Report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: January 14, 2019

/s/ Frank McEnulty

Frank McEnulty

Chief Executive Officer

(Principal Executive Officer)

EX-31.2 4 cmxc_ex312.htm CERTIFICATION ex-31.2

CELL MEDX CORP.

CERTIFICATIONS PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Yanika Silina, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the period ending November 30, 2018, of Cell MedX Corp.;

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: January 14, 2019

/s/ Yanika Silina

Yanika Silina

Chief Financial Officer

(Principal Accounting Officer)

EX-32.1 5 cmxc_ex321.htm CERTIFICATION ex-32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Cell MedX Corp. (the “Company”) on Form 10-Q for the period ending November 30, 2018, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, in the capacity and on the date indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: January 14, 2019

/s/ Frank McEnulty

Frank McEnulty

Chief Executive Officer

(Principal Executive Officer)

EX-32.2 6 cmxc_ex322.htm CERTIFICATION ex-32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: January 14, 2019

/s/Yanika Silina

Yanika Silina

Chief Financial Officer

(Principal Accounting Officer)

EX-101.INS 7 cmxc-20181130.xml

24377

8200

59787

10793

9216

26266

93380

45259

95152

45259

668980

594716

7493

20600

360085

334317

1532206

1118677

1532206

1118677

44283

4916201

14400 14400

-6050841

9885

2539

95152

45259

0.001

300000000

44282749

522407

110

38434

66678

61422

130638

644881

24448

33586

52077

88061

33633

41491

183367

88994

6130

124869

181063

366192

1006424

2648

327

-127517

-181390

6477

1464

7346

-170

-121040

-179926

-363636

-1014835

-0.01

-0.02

44282749

41997595

44282749

41116310

40244605

40245

3294224

-4504043

247

-1169327

106931

522407

1480000

1480

368520

370000

2318144

2318

577218

579536

-170

-1014665

44042749

44043

4869300

-5518708

-605288

1541

240000 240 45360 14400 60000

2462

-532133

44282749

44283

4916201

14400

-6050841

2539

-1073418

7346

-370982

44282749

44283

4916201

14400

-6421823

9885

-1437054

-370982

-1014665

4790

8241

77557

522407

387

-2788

5127

106931

-50072

-21133

16823

-99028

75053

66244

-13107

-74719

250000

59588

26352

30246

-63434

-333204

1915

-1915

22704

47004

25318

370000

75875

372614

5651

1464

16177

40874

8200

67494

24377

108368

579536

NOTE 1 - ORGANIZATION AND NATURE OF OPERATIONS   Cell MedX Corp. (the Company) was incorporated under the laws of the State of Nevada. On April 26, 2016, the Company formed a subsidiary, Cell MedX (Canada) Corp. (Cell MedX Canada) under the laws of the province of British Columbia.   The Company is in an early development stage focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness and alleviate complications associated with medical conditions including, but not limited to, diabetes, Parkinsons disease, and high blood pressure.   Unaudited Interim Financial Statements The unaudited interim consolidated financial statements of the Company have been prepared in accordance with United States generally accepted accounting principles (GAAP) for interim financial information and the rules and regulations of the Securities and Exchange Commission (the SEC). They do not include all information and footnotes required by GAAP for complete financial statements. Except as disclosed herein, there have been no material changes in the information disclosed in the notes to the consolidated financial statements for the year ended May 31, 2018, included in the Companys Annual Report on Form 10-K, filed with the SEC. The interim unaudited consolidated financial statements should be read in conjunction with those audited consolidated financial statements included in Form 10-K. In the opinion of management, all adjustments considered necessary for fair presentation, consisting solely of normal recurring adjustments, have been made. Operating results for the three and six months ended November 30, 2018, are not necessarily indicative of the results that may be expected for the year ending May 31, 2019.   Going concern The accompanying unaudited interim consolidated condensed financial statements have been prepared assuming the Company will continue as a going concern. As of November 30, 2018, the Company has not achieved profitable operations and has accumulated a deficit of $6,421,823. Continuation as a going concern is dependent upon the ability of the Company to obtain the necessary financing to meet obligations and pay its liabilities arising from normal business operations when they come due and ultimately upon its ability to achieve profitable operations. The outcome of these matters cannot be predicted with any certainty at this time and raises substantial doubt that the Company will be able to continue as a going concern. These financial statements do not include any adjustments to the amounts and classification of assets and liabilities that may be necessary should the Company be unable to continue as a going concern. Management intends to obtain additional funding by borrowing funds from its directors and officers, issuing promissory notes and/or a private placement of common stock.

NOTE 2 - RELATED PARTY TRANSACTIONS   Amounts due to related parties, other than notes payable to related parties (Note 7) at November 30, 2018 and May 31, 2018:   <table border="0" cellspacing="0" cellpadding="0" width="99%" style='width:99.0%;border-collapse:collapse'> <tr align="left"> <td valign="top" style='border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'>   </td> <td colspan="2" valign="bottom" style='border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'> November 30, 2018 </td> <td valign="bottom" style='border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'>   </td> <td colspan="2" valign="bottom" style='border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'> May 31, 2018 </td> </tr> <tr align="left"> <td valign="top" style='border:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> Due to the former Chief Executive Officer (CEO) and director </td> <td valign="bottom" style='border:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> $ </td> <td valign="bottom" style='border:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 52,626 </td> <td valign="bottom" style='border:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'>   </td> <td valign="bottom" style='border:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> $ </td> <td valign="bottom" style='border:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 54,275 </td> </tr> <tr align="left"> <td valign="top" style='padding:0in 5.4pt 0in 5.4pt'> Due to a director, CEO and President </td> <td valign="bottom" style='padding:0in 5.4pt 0in 5.4pt'>   </td> <td valign="bottom" style='padding:0in 5.4pt 0in 5.4pt'> 54,000 </td> <td valign="bottom" style='padding:0in 5.4pt 0in 5.4pt'>   </td> <td valign="bottom" style='padding:0in 5.4pt 0in 5.4pt'>   </td> <td valign="bottom" style='padding:0in 5.4pt 0in 5.4pt'> 32,400 </td> </tr> <tr align="left"> <td valign="top" style='background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> Due to the Chief Financial Officer (CFO) </td> <td valign="bottom" style='background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'>   </td> <td valign="bottom" style='background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 30,735 </td> <td valign="bottom" style='background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'>   </td> <td valign="bottom" style='background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'>   </td> <td valign="bottom" style='background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 20,790 </td> </tr> <tr align="left"> <td valign="top" style='padding:0in 5.4pt 0in 5.4pt'> Due to the Vice President (VP), Technology and Operations </td> <td valign="bottom" style='padding:0in 5.4pt 0in 5.4pt'>   </td> <td valign="bottom" style='padding:0in 5.4pt 0in 5.4pt'> 54,895 </td> <td valign="bottom" style='padding:0in 5.4pt 0in 5.4pt'>   </td> <td valign="bottom" style='padding:0in 5.4pt 0in 5.4pt'>   </td> <td valign="bottom" style='padding:0in 5.4pt 0in 5.4pt'> 59,035 </td> </tr> <tr align="left"> <td valign="top" style='background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> Due to the former Chief Medical Officer </td> <td valign="bottom" style='background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'>   </td> <td valign="bottom" style='background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 81,059 </td> <td valign="bottom" style='background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'>   </td> <td valign="bottom" style='background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'>   </td> <td valign="bottom" style='background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 81,059 </td> </tr> <tr align="left"> <td valign="top" style='border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> Due to the former VP, Corporate Strategy </td> <td valign="bottom" style='border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td valign="bottom" style='border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> 86,770 </td> <td valign="bottom" style='border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td valign="bottom" style='border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td valign="bottom" style='border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> 86,758 </td> </tr> <tr align="left"> <td valign="top" style='border:none;border-bottom:double windowtext 1.5pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> Due to related parties </td> <td valign="bottom" style='border:none;border-bottom:double windowtext 1.5pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> $ </td> <td valign="bottom" style='border:none;border-bottom:double windowtext 1.5pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 360,085 </td> <td valign="bottom" style='border:none;border-bottom:double windowtext 1.5pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'>   </td> <td valign="bottom" style='border:none;border-bottom:double windowtext 1.5pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> $ </td> <td valign="bottom" style='border:none;border-bottom:double windowtext 1.5pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 334,317 </td> </tr> </table>   These amounts are unsecured, due on demand and bear no interest.   During the six-month periods ended November 30, 2018 and 2017, the Company had the following transactions with related parties:   <table border="0" cellspacing="0" cellpadding="0" width="98%" style='border-collapse:collapse'> <tr align="left"> <td width="409" valign="top" style='width:306.9pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="101" colspan="2" valign="bottom" style='width:75.65pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0'> November 30, 2018 </td> <td width="16" valign="bottom" style='width:11.9pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="101" colspan="2" valign="bottom" style='width:75.65pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'> November 30, 2017 </td> </tr> <tr align="left"> <td width="409" valign="top" style='width:306.9pt;border:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> Management fees incurred to the CEO </td> <td width="28" valign="bottom" style='width:20.8pt;border:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> $ </td> <td width="73" valign="bottom" style='width:54.85pt;border:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 21,600 </td> <td width="16" valign="bottom" style='width:11.9pt;border:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="28" valign="bottom" style='width:20.8pt;border:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> $ </td> <td width="73" valign="bottom" style='width:54.85pt;border:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 21,600 </td> </tr> <tr align="left"> <td width="409" valign="top" style='width:306.9pt;padding:0in 5.4pt 0in 5.4pt'> Management fees incurred to the CFO </td> <td width="28" valign="bottom" style='width:20.8pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="73" valign="bottom" style='width:54.85pt;padding:0in 5.4pt 0in 5.4pt'> 6,000 </td> <td width="16" valign="bottom" style='width:11.9pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="28" valign="bottom" style='width:20.8pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="73" valign="bottom" style='width:54.85pt;padding:0in 5.4pt 0in 5.4pt'> 6,000 </td> </tr> <tr align="left"> <td width="409" valign="top" style='width:306.9pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> Stock-based compensation incurred to the CFO </td> <td width="28" valign="bottom" style='width:20.8pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="73" valign="bottom" style='width:54.85pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> -- </td> <td width="16" valign="bottom" style='width:11.9pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="28" valign="bottom" style='width:20.8pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="73" valign="bottom" style='width:54.85pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 89,556 </td> </tr> <tr align="left"> <td width="409" valign="top" style='width:306.9pt;padding:0in 5.4pt 0in 5.4pt'> Consulting fees incurred to the VP, Technology and Operations </td> <td width="28" valign="bottom" style='width:20.8pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="73" valign="bottom" style='width:54.85pt;padding:0in 5.4pt 0in 5.4pt'> 25,638 </td> <td width="16" valign="bottom" style='width:11.9pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="28" valign="bottom" style='width:20.8pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="73" valign="bottom" style='width:54.85pt;padding:0in 5.4pt 0in 5.4pt'> 23,475 </td> </tr> <tr align="left"> <td width="409" valign="top" style='width:306.9pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> Stock-based compensation incurred to the Former Chief Medical Officer </td> <td width="28" valign="bottom" style='width:20.8pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="73" valign="bottom" style='width:54.85pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> -- </td> <td width="16" valign="bottom" style='width:11.9pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="28" valign="bottom" style='width:20.8pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="73" valign="bottom" style='width:54.85pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 17,375 </td> </tr> <tr align="left"> <td width="409" valign="top" style='width:306.9pt;padding:0in 5.4pt 0in 5.4pt'> Accrued interest expense incurred to the Companys shareholder (Note 7) </td> <td width="28" valign="bottom" style='width:20.8pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="73" valign="bottom" style='width:54.85pt;padding:0in 5.4pt 0in 5.4pt'> 4,294 </td> <td width="16" valign="bottom" style='width:11.9pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="28" valign="bottom" style='width:20.8pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="73" valign="bottom" style='width:54.85pt;padding:0in 5.4pt 0in 5.4pt'> 3,170 </td> </tr> <tr align="left"> <td width="409" valign="top" style='width:306.9pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:double windowtext 1.5pt;border-right:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> Total transactions with related parties </td> <td width="28" valign="bottom" style='width:20.8pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:double windowtext 1.5pt;border-right:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> $ </td> <td width="73" valign="bottom" style='width:54.85pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:double windowtext 1.5pt;border-right:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 57,532 </td> <td width="16" valign="bottom" style='width:11.9pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:double windowtext 1.5pt;border-right:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="28" valign="bottom" style='width:20.8pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:double windowtext 1.5pt;border-right:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> $ </td> <td width="73" valign="bottom" style='width:54.85pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:double windowtext 1.5pt;border-right:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 161,176 </td> </tr> </table>

NOTE 3 - INVENTORY   As at November 30, 2018, the inventory consisted of supplies held for resale valued at $13,694 (May 31, 2018 - $10,793) and work in progress, which was associated with manufacturing of eBalance devices, valued at $46,093 (May 31, 2018 - $Nil).

NOTE 4 - OTHER CURRENT ASSETS   As at November 30, 2018, other current assets consisted of $2,572 in prepaid expenses (May 31, 2018 - $23,915) and $6,644 in receivables associated with GST Cell MedX Canada paid on the taxable supplies (May 31, 2018 - $2,351).

NOTE 5 - EQUIPMENT   Amortization schedule for the equipment at November 30, 2018 and May 31, 2018:   <table border="0" cellspacing="0" cellpadding="0" width="76%" style='width:76.84%;border-collapse:collapse'> <tr align="left"> <td valign="top" style='border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="26%" colspan="2" valign="bottom" style='width:26.2%;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'> November 30, 2018 </td> <td valign="bottom" style='border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'>   </td> <td colspan="2" valign="bottom" style='border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'> May 31, 2018 </td> </tr> <tr align="left"> <td valign="top" style='border:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> Book value, beginning of the period </td> <td width="5%" valign="bottom" style='width:5.66%;border:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> $ </td> <td valign="bottom" style='border:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> -- </td> <td valign="bottom" style='border:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'>   </td> <td valign="bottom" style='border:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> $ </td> <td valign="bottom" style='border:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 193,571 </td> </tr> <tr align="left"> <td valign="top" style='padding:0in 5.4pt 0in 5.4pt'> Changes during the period </td> <td width="5%" valign="bottom" style='width:5.66%;padding:0in 5.4pt 0in 5.4pt'>   </td> <td valign="bottom" style='padding:0in 5.4pt 0in 5.4pt'> 1,915 </td> <td valign="bottom" style='padding:0in 5.4pt 0in 5.4pt'>   </td> <td valign="bottom" style='padding:0in 5.4pt 0in 5.4pt'>   </td> <td valign="bottom" style='padding:0in 5.4pt 0in 5.4pt'> (193,571) </td> </tr> <tr align="left"> <td valign="top" style='background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> Amortization </td> <td width="5%" valign="bottom" style='width:5.66%;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'>   </td> <td valign="bottom" style='background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> (110) </td> <td valign="bottom" style='background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'>   </td> <td valign="bottom" style='background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'>   </td> <td valign="bottom" style='background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> -- </td> </tr> <tr align="left"> <td valign="top" style='border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> Foreign exchange </td> <td width="5%" valign="bottom" style='width:5.66%;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td valign="bottom" style='border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> (33) </td> <td valign="bottom" style='border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td valign="bottom" style='border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td valign="bottom" style='border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> -- </td> </tr> <tr align="left"> <td valign="top" style='border:none;border-bottom:double windowtext 1.5pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> Book value, end of the period </td> <td width="5%" valign="bottom" style='width:5.66%;border:none;border-bottom:double windowtext 1.5pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> $ </td> <td valign="bottom" style='border:none;border-bottom:double windowtext 1.5pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 1,772 </td> <td valign="bottom" style='border:none;border-bottom:double windowtext 1.5pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'>   </td> <td valign="bottom" style='border:none;border-bottom:double windowtext 1.5pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> $ </td> <td valign="bottom" style='border:none;border-bottom:double windowtext 1.5pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> -- </td> </tr> </table>

NOTE 6 - UNEARNED REVENUE   As at May 31, 2018, the Company recorded $301,277 (May 31, 2018 - $51,585) in unearned revenue for deposits, of which $250,000 represented a refundable deposit for exclusive worldwide distribution rights the Company received from an arms-length party under the terms of the letter of intent (the LOI) the Company signed on September 10, 2018.

NOTE 7 - NOTES AND ADVANCES PAYABLE   The tables below summarize the short-term loans and advances outstanding as at November 30, 2018 and May 31, 2018:   <table border="0" cellspacing="0" cellpadding="0" width="90%" style='border-collapse:collapse'> <tr align="left"> <td width="575" colspan="15" valign="bottom" style='width:430.9pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> As at November 30, 2018 </td> </tr> <tr align="left"> <td width="111" colspan="3" valign="bottom" style='width:82.95pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> Principal Outstanding </td> <td width="104" colspan="2" valign="bottom" style='width:78.0pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> Interest Rate per Annum </td> <td width="160" colspan="3" valign="bottom" style='width:120.25pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="92" colspan="4" valign="bottom" style='width:69.15pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> Accrued Interest </td> <td width="107" colspan="3" valign="bottom" style='width:80.55pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> Total Book Value </td> </tr> <tr align="left"> <td width="34" valign="bottom" style='width:25.55pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> $ </td> <td width="77" colspan="2" valign="bottom" style='width:57.4pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 29,457 </td> <td width="104" colspan="2" valign="bottom" style='width:78.0pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 6% </td> <td width="160" colspan="3" valign="bottom" style='width:120.25pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> Non-convertible </td> <td width="34" colspan="2" valign="bottom" style='width:25.55pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> $ </td> <td width="58" colspan="2" valign="bottom" style='width:43.6pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 716 </td> <td width="34" colspan="2" valign="bottom" style='width:25.55pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> $ </td> <td width="73" valign="bottom" style='width:55.0pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 30,173 </td> </tr> <tr align="left"> <td width="34" valign="bottom" style='width:25.55pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="77" colspan="2" valign="bottom" style='width:57.4pt;padding:0in 5.4pt 0in 5.4pt'> 115,964 </td> <td width="104" colspan="2" valign="bottom" style='width:78.0pt;padding:0in 5.4pt 0in 5.4pt'> 0%-12% </td> <td width="160" colspan="3" valign="bottom" style='width:120.25pt;padding:0in 5.4pt 0in 5.4pt'> Former related party(1) </td> <td width="34" colspan="2" valign="bottom" style='width:25.55pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="58" colspan="2" valign="bottom" style='width:43.6pt;padding:0in 5.4pt 0in 5.4pt'> 8,184 </td> <td width="34" colspan="2" valign="bottom" style='width:25.55pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="73" valign="bottom" style='width:55.0pt;padding:0in 5.4pt 0in 5.4pt'> 124,148 </td> </tr> <tr align="left"> <td width="34" valign="bottom" style='width:25.55pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="77" colspan="2" valign="bottom" style='width:57.4pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 40,050 </td> <td width="104" colspan="2" valign="bottom" style='width:78.0pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 0% </td> <td width="160" colspan="3" valign="bottom" style='width:120.25pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> Advances(2) </td> <td width="34" colspan="2" valign="bottom" style='width:25.55pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="58" colspan="2" valign="bottom" style='width:43.6pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> -- </td> <td width="34" colspan="2" valign="bottom" style='width:25.55pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="73" valign="bottom" style='width:55.0pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 40,050 </td> </tr> <tr align="left"> <td width="34" valign="bottom" style='width:25.55pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:double windowtext 1.5pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'> $ </td> <td width="77" colspan="2" valign="bottom" style='width:57.4pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:double windowtext 1.5pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'> 185,471 </td> <td width="104" colspan="2" valign="bottom" style='width:78.0pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:double windowtext 1.5pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="160" colspan="3" valign="bottom" style='width:120.25pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:double windowtext 1.5pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="34" colspan="2" valign="bottom" style='width:25.55pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:double windowtext 1.5pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'> $ </td> <td width="58" colspan="2" valign="bottom" style='width:43.6pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:double windowtext 1.5pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'> 8,900 </td> <td width="34" colspan="2" valign="bottom" style='width:25.55pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:double windowtext 1.5pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'> $ </td> <td width="73" valign="bottom" style='width:55.0pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:double windowtext 1.5pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'> 194,371 </td> </tr> <tr align="left"> <td width="575" colspan="15" valign="bottom" style='width:430.9pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>   </td> </tr> <tr align="left"> <td width="575" colspan="15" valign="bottom" style='width:430.9pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> As at May 31, 2018 </td> </tr> <tr align="left"> <td width="112" colspan="4" valign="bottom" style='width:84.1pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> Principal Outstanding </td> <td width="105" colspan="2" valign="bottom" style='width:79.05pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> Interest Rate per Annum </td> <td width="155" valign="bottom" style='width:116.0pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="93" colspan="4" valign="bottom" style='width:70.1pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> Accrued Interest </td> <td width="109" colspan="4" valign="bottom" style='width:81.65pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> Total Book Value </td> </tr> <tr align="left"> <td width="35" colspan="2" valign="bottom" style='width:25.95pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> $ </td> <td width="78" colspan="2" valign="bottom" style='width:58.15pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 6,000 </td> <td width="105" colspan="2" valign="bottom" style='width:79.05pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 6% </td> <td width="155" valign="bottom" style='width:116.0pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> Non-convertible </td> <td width="35" colspan="2" valign="bottom" style='width:25.9pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> $ </td> <td width="59" colspan="2" valign="bottom" style='width:44.2pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 225 </td> <td width="35" colspan="2" valign="bottom" style='width:25.9pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> $ </td> <td width="74" colspan="2" valign="bottom" style='width:55.75pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 6,225 </td> </tr> <tr align="left"> <td width="35" colspan="2" valign="bottom" style='width:25.95pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="78" colspan="2" valign="bottom" style='width:58.15pt;padding:0in 5.4pt 0in 5.4pt'> 95,570 </td> <td width="105" colspan="2" valign="bottom" style='width:79.05pt;padding:0in 5.4pt 0in 5.4pt'> 6%-12% </td> <td width="155" valign="bottom" style='width:116.0pt;padding:0in 5.4pt 0in 5.4pt'> Former related party </td> <td width="35" colspan="2" valign="bottom" style='width:25.9pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="59" colspan="2" valign="bottom" style='width:44.2pt;padding:0in 5.4pt 0in 5.4pt'> 4,066 </td> <td width="35" colspan="2" valign="bottom" style='width:25.9pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="74" colspan="2" valign="bottom" style='width:55.75pt;padding:0in 5.4pt 0in 5.4pt'> 99,636 </td> </tr> <tr align="left"> <td width="35" colspan="2" valign="bottom" style='width:25.95pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="78" colspan="2" valign="bottom" style='width:58.15pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 11,598 </td> <td width="105" colspan="2" valign="bottom" style='width:79.05pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 0% </td> <td width="155" valign="bottom" style='width:116.0pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> Advances </td> <td width="35" colspan="2" valign="bottom" style='width:25.9pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="59" colspan="2" valign="bottom" style='width:44.2pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> -- </td> <td width="35" colspan="2" valign="bottom" style='width:25.9pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="74" colspan="2" valign="bottom" style='width:55.75pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 11,598 </td> </tr> <tr align="left"> <td width="35" colspan="2" valign="bottom" style='width:25.95pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:double windowtext 1.5pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'> $ </td> <td width="78" colspan="2" valign="bottom" style='width:58.15pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:double windowtext 1.5pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'> 113,168 </td> <td width="105" colspan="2" valign="bottom" style='width:79.05pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:double windowtext 1.5pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="155" valign="bottom" style='width:116.0pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:double windowtext 1.5pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="35" colspan="2" valign="bottom" style='width:25.9pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:double windowtext 1.5pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'> $ </td> <td width="59" colspan="2" valign="bottom" style='width:44.2pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:double windowtext 1.5pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'> 4,291 </td> <td width="35" colspan="2" valign="bottom" style='width:25.9pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:double windowtext 1.5pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'> $ </td> <td width="74" colspan="2" valign="bottom" style='width:55.75pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:double windowtext 1.5pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'> 117,459 </td> </tr> <tr align="left"> <td width="40" style='border:none'></td> <td width="1" style='border:none'></td> <td width="89" style='border:none'></td> <td width="2" style='border:none'></td> <td width="120" style='border:none'></td> <td width="3" style='border:none'></td> <td width="181" style='border:none'></td> <td width="3" style='border:none'></td> <td width="37" style='border:none'></td> <td width="3" style='border:none'></td> <td width="66" style='border:none'></td> <td width="2" style='border:none'></td> <td width="39" style='border:none'></td> <td width="1" style='border:none'></td> <td width="86" style='border:none'></td> </tr> </table>   (1) Former Related Party Loans Payable During the six-month period ended November 30, 2018, the Company entered into three separate unsecure loan agreements with Mr. Richard Jeffs, our shareholder, for a total of $23,029 (CAD$30,000) (May 31, 2018 - $34,840):   <table border="0" cellspacing="0" cellpadding="0" width="98%" style='border-collapse:collapse'> <tr align="left"> <td width="97" valign="bottom" style='width:72.8pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'> Date </td> <td width="73" valign="bottom" style='width:54.4pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'> Principal (CAD$) </td> <td width="60" valign="bottom" style='width:45.05pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'> Interest Rate </td> <td width="257" valign="bottom" style='width:193.05pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'> Additional Terms </td> <td width="66" valign="bottom" style='width:49.6pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'> Accrued Interest (CAD$) </td> <td width="78" valign="bottom" style='width:58.55pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'> Total Book Value (CAD$) </td> </tr> <tr align="left"> <td width="97" valign="top" style='width:72.8pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> June 7, 2018 </td> <td width="73" valign="top" style='width:54.4pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> $10,500 </td> <td width="60" valign="top" style='width:45.05pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 12% </td> <td width="257" valign="top" style='width:193.05pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> Convertible into units of the Companys common stock at $0.10 per unit. Includes CAD$500 finance fee, added to principal. Payable on demand. </td> <td width="66" valign="top" style='width:49.6pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> $622 </td> <td width="78" valign="top" style='width:58.55pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> $11,122 </td> </tr> <tr align="left"> <td width="97" valign="top" style='width:72.8pt;padding:0in 5.4pt 0in 5.4pt'> July 3, 2018 </td> <td width="73" valign="top" style='width:54.4pt;padding:0in 5.4pt 0in 5.4pt'> $10,000 </td> <td width="60" valign="top" style='width:45.05pt;padding:0in 5.4pt 0in 5.4pt'> 0% </td> <td width="257" valign="top" style='width:193.05pt;padding:0in 5.4pt 0in 5.4pt'> Short-term loan payable within 14 days after grant. As at November 30, 2018, the loan has not been repaid and therefore was payable on demand. </td> <td width="66" valign="top" style='width:49.6pt;padding:0in 5.4pt 0in 5.4pt'> -- </td> <td width="78" valign="top" style='width:58.55pt;padding:0in 5.4pt 0in 5.4pt'> 10,000 </td> </tr> <tr align="left"> <td width="97" valign="top" style='width:72.8pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> August 1, 2018 </td> <td width="73" valign="top" style='width:54.4pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> $10,000 </td> <td width="60" valign="top" style='width:45.05pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 12% </td> <td width="257" valign="top" style='width:193.05pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> Convertible into units of the Companys common stock on the terms and at a price of the private placement offering open at the time of conversion. Payable on demand. </td> <td width="66" valign="top" style='width:49.6pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 404 </td> <td width="78" valign="top" style='width:58.55pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 10,404 </td> </tr> <tr align="left"> <td width="97" valign="bottom" style='width:72.8pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:double windowtext 1.5pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="73" valign="top" style='width:54.4pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:double windowtext 1.5pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'> $30,500 </td> <td width="60" valign="bottom" style='width:45.05pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:double windowtext 1.5pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="257" valign="bottom" style='width:193.05pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:double windowtext 1.5pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="66" valign="top" style='width:49.6pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:double windowtext 1.5pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'> $1,026 </td> <td width="78" valign="top" style='width:58.55pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:double windowtext 1.5pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'> $31,526 </td> </tr> </table>   (2) Advances Payable During the six-month period ended November 30, 2018, the Company borrowed $28,871 from unrelated parties. The advances are non-interest bearing, unsecured and payable on demand.   Interest Expense During the six-month period ended November 30, 2018, the Company recorded $4,790 (2017 - $8,241) in interest expense associated with its liabilities under the notes and advances payable.

NOTE 8 - SHARE CAPITAL   Options The changes in the number of stock options outstanding during the six-month period ended November 30, 2018, and for the year ended May 31, 2018 are as follows:   <table border="0" cellspacing="0" cellpadding="0" width="99%" style='border-collapse:collapse'> <tr align="left"> <td width="223" valign="top" style='width:167.6pt;border:none;border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="198" colspan="3" valign="bottom" style='width:148.5pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'> Six months ended November 30, 2018 </td> <td width="20" valign="bottom" style='width:15.1pt;border:none;border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="190" colspan="3" valign="bottom" style='width:142.8pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'> Year ended May 31, 2018 </td> </tr> <tr align="left"> <td width="223" valign="top" style='width:167.6pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="96" valign="bottom" style='width:71.75pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> Number of options </td> <td width="102" colspan="2" valign="bottom" style='width:76.75pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'> Weighted average exercise price </td> <td width="20" valign="bottom" style='width:15.1pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="86" valign="bottom" style='width:64.7pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> Number of options </td> <td width="104" colspan="2" valign="bottom" style='width:78.1pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'> Weighted average exercise price </td> </tr> <tr align="left"> <td width="223" valign="top" style='width:167.6pt;border:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> Options outstanding, beginning </td> <td width="96" valign="bottom" style='width:71.75pt;border:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 9,450,000 </td> <td width="44" valign="bottom" style='width:33.2pt;border:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> $ </td> <td width="58" valign="bottom" style='width:43.55pt;border:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 0.35 </td> <td width="20" valign="bottom" style='width:15.1pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="86" valign="bottom" style='width:64.7pt;border:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 7,550,000 </td> <td width="46" valign="bottom" style='width:34.55pt;border:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> $ </td> <td width="58" valign="bottom" style='width:43.55pt;border:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 0.35 </td> </tr> <tr align="left"> <td width="223" valign="top" style='width:167.6pt;padding:0in 5.4pt 0in 5.4pt'> Options granted </td> <td width="96" valign="bottom" style='width:71.75pt;padding:0in 5.4pt 0in 5.4pt'> -- </td> <td width="44" valign="bottom" style='width:33.2pt;padding:0in 5.4pt 0in 5.4pt'> $ </td> <td width="58" valign="bottom" style='width:43.55pt;padding:0in 5.4pt 0in 5.4pt'> n/a </td> <td width="20" valign="bottom" style='width:15.1pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="86" valign="bottom" style='width:64.7pt;padding:0in 5.4pt 0in 5.4pt'> 2,050,000 </td> <td width="46" valign="bottom" style='width:34.55pt;padding:0in 5.4pt 0in 5.4pt'> $ </td> <td width="58" valign="bottom" style='width:43.55pt;padding:0in 5.4pt 0in 5.4pt'> 0.35 </td> </tr> <tr align="left"> <td width="223" valign="top" style='width:167.6pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> Options expired </td> <td width="96" valign="bottom" style='width:71.75pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> -- </td> <td width="44" valign="bottom" style='width:33.2pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> $ </td> <td width="58" valign="bottom" style='width:43.55pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> n/a </td> <td width="20" valign="bottom" style='width:15.1pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="86" valign="bottom" style='width:64.7pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> (150,000) </td> <td width="46" valign="bottom" style='width:34.55pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> $ </td> <td width="58" valign="bottom" style='width:43.55pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 0.20 </td> </tr> <tr align="left"> <td width="223" valign="top" style='width:167.6pt;padding:0in 5.4pt 0in 5.4pt'> Options cancelled </td> <td width="96" valign="bottom" style='width:71.75pt;padding:0in 5.4pt 0in 5.4pt'> (2,400,000) </td> <td width="44" valign="bottom" style='width:33.2pt;padding:0in 5.4pt 0in 5.4pt'> $ </td> <td width="58" valign="bottom" style='width:43.55pt;padding:0in 5.4pt 0in 5.4pt'> 0.67 </td> <td width="20" valign="bottom" style='width:15.1pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="86" valign="bottom" style='width:64.7pt;padding:0in 5.4pt 0in 5.4pt'> -- </td> <td width="46" valign="bottom" style='width:34.55pt;padding:0in 5.4pt 0in 5.4pt'> $ </td> <td width="58" valign="bottom" style='width:43.55pt;padding:0in 5.4pt 0in 5.4pt'> n/a </td> </tr> <tr align="left"> <td width="223" valign="top" style='width:167.6pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:double windowtext 1.5pt;border-right:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> Options outstanding, ending </td> <td width="96" valign="bottom" style='width:71.75pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:double windowtext 1.5pt;border-right:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 7,050,000 </td> <td width="44" valign="bottom" style='width:33.2pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:double windowtext 1.5pt;border-right:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> $ </td> <td width="58" valign="bottom" style='width:43.55pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:double windowtext 1.5pt;border-right:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 0.24 </td> <td width="20" valign="bottom" style='width:15.1pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="86" valign="bottom" style='width:64.7pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:double windowtext 1.5pt;border-right:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 9,450,000 </td> <td width="46" valign="bottom" style='width:34.55pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:double windowtext 1.5pt;border-right:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> $ </td> <td width="58" valign="bottom" style='width:43.55pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:double windowtext 1.5pt;border-right:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 0.35 </td> </tr> </table>   Details of options outstanding and exercisable as at November 30, 2018, are as follows:   <table border="0" cellspacing="0" cellpadding="0" width="70%" style='width:70.0%;border-collapse:collapse'> <tr align="left"> <td valign="bottom" style='border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'> Exercise price </td> <td valign="bottom" style='border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'> Grant date </td> <td valign="bottom" style='border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'> Number of options Outstanding and exercisable </td> </tr> <tr align="left"> <td valign="bottom" style='border:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> $0.05 </td> <td valign="bottom" style='border:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> November 25, 2014 </td> <td valign="bottom" style='border:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 2,500,000 </td> </tr> <tr align="left"> <td valign="bottom" style='padding:0in 5.4pt 0in 5.4pt'> $0.35 </td> <td valign="bottom" style='padding:0in 5.4pt 0in 5.4pt'> August 5, 2015 </td> <td valign="bottom" style='padding:0in 5.4pt 0in 5.4pt'> 2,500,000 </td> </tr> <tr align="left"> <td valign="bottom" style='border:none;border-bottom:solid windowtext 1.0pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> $0.35 </td> <td valign="bottom" style='border:none;border-bottom:solid windowtext 1.0pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> August 24, 2017 </td> <td valign="bottom" style='border:none;border-bottom:solid windowtext 1.0pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 2,050,000 </td> </tr> <tr align="left"> <td valign="bottom" style='border:none;border-bottom:double windowtext 1.5pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td valign="bottom" style='border:none;border-bottom:double windowtext 1.5pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td valign="bottom" style='border:none;border-bottom:double windowtext 1.5pt;padding:0in 5.4pt 0in 5.4pt'> 7,050,000 </td> </tr> </table>   At November 30, 2018, the weighted average remaining contractual life of the stock options outstanding was 2.45 years.   Warrants The changes in the number of warrants outstanding during the six-month period ended November 30, 2018, and for the year ended May 31, 2018 are as follows:   <table border="1" cellspacing="0" cellpadding="0" width="81%" style='border-collapse:collapse;border:none'> <tr align="left"> <td width="237" valign="top" style='width:177.8pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="136" valign="bottom" style='width:102.1pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'> Six months ended November 30, 2018 </td> <td width="23" valign="bottom" style='width:17.35pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="125" valign="bottom" style='width:93.95pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'> Year ended May 31, 2018 </td> </tr> <tr align="left"> <td width="237" valign="top" style='width:177.8pt;border:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> Warrants outstanding, beginning </td> <td width="136" valign="bottom" style='width:102.1pt;border:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 12,814,605 </td> <td width="23" valign="bottom" style='width:17.35pt;border:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="125" valign="bottom" style='width:93.95pt;border:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 11,094,605 </td> </tr> <tr align="left"> <td width="237" valign="top" style='width:177.8pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> Warrants issued </td> <td width="136" valign="bottom" style='width:102.1pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> -- </td> <td width="23" valign="bottom" style='width:17.35pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="125" valign="bottom" style='width:93.95pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> 1,720,000 </td> </tr> <tr align="left"> <td width="237" valign="top" style='width:177.8pt;border:none;border-bottom:double windowtext 1.5pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> Warrants outstanding, ending </td> <td width="136" valign="bottom" style='width:102.1pt;border:none;border-bottom:double windowtext 1.5pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 12,814,605 </td> <td width="23" valign="bottom" style='width:17.35pt;border:none;border-bottom:double windowtext 1.5pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="125" valign="bottom" style='width:93.95pt;border:none;border-bottom:double windowtext 1.5pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 12,814,605 </td> </tr> </table>   Details of warrants outstanding as at November 30, 2018, are as follows:   <table border="0" cellspacing="0" cellpadding="0" width="99%" style='width:99.0%;margin-left:.9pt;border-collapse:collapse'> <tr align="left"> <td valign="bottom" style='border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'> Exercise price </td> <td valign="bottom" style='border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'> Grant Date </td> <td valign="bottom" style='border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'> Number of warrants exercisable </td> </tr> <tr align="left"> <td valign="top" style='border:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> $0.40 during the period from March 3, 2018 to March 3, 2019 $0.60 during the period from March 3, 2019 to March 3, 2020 $0.75 during the period from March 3, 2020 to March 3, 2021 </td> <td valign="top" style='border:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> March 3, 2016 </td> <td valign="top" style='border:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 2,000,000 </td> </tr> <tr align="left"> <td valign="top" style='padding:0in 5.4pt 0in 5.4pt'> $1.00 during the period from October 12, 2018 to October 12, 2019 $1.25 during the period from October 12, 2019 to October 12, 2020 $1.50 during the period from October 12, 2020 to October 12, 2021 </td> <td valign="top" style='padding:0in 5.4pt 0in 5.4pt'> October 12, 2016 </td> <td valign="top" style='padding:0in 5.4pt 0in 5.4pt'> 9,094,605 </td> </tr> <tr align="left"> <td valign="top" style='background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> $1.00 during the period from October 12, 2018 to October 12, 2019 $1.50 during the period from October 12, 2019 to October 12, 2020 </td> <td valign="top" style='background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> October 12, 2017 </td> <td valign="top" style='background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 1,480,000 </td> </tr> <tr align="left"> <td valign="top" style='border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> $0.50 up to February 7, 2019 $1.00 during the period from February 7, 2019 to February 7, 2020 $1.50 during the period from February 7, 2020 to February 7, 2021 </td> <td valign="top" style='border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> February 7, 2018 </td> <td valign="top" style='border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> 240,000 </td> </tr> <tr align="left"> <td valign="bottom" style='border:none;border-bottom:double windowtext 1.5pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'>   </td> <td valign="bottom" style='border:none;border-bottom:double windowtext 1.5pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'>   </td> <td valign="bottom" style='border:none;border-bottom:double windowtext 1.5pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 12,814,605 </td> </tr> </table>   At November 30, 2018, the weighted average life and price of the warrants was 2.64 years and $0.83, respectively.

NOTE 9 - SUBSEQUENT EVENT   Subsequent to November 30, 2018, the Company entered into a credit line agreement (the Agreement) with Mr. Jeffs (the Lender), for an unsecured line of credit of up to $250,000 (the Credit Line) of which $100,000 was advanced to the Company on December 20, 2018. The funds advanced under the Credit Line accumulate interest at a rate of 6% per annum compounded monthly.   In consideration for the Credit Line the Company issued to the Lender non-transferable share purchase warrants (the Warrants) to purchase up to 5,000,000 shares exercisable at $0.05 per share and expiring on December 27, 2021. The Warrants vest at a rate of 20 warrants for every $1 drawn on the Credit Line, with 2,000,000 warrants having vested on the grant date.   In addition, in recognition of $124,148 previously advanced by the Lender, the Company issued to the Lender non-transferable share purchase warrants (the Additional Warrants) to purchase up to 2,482,960 shares exercisable at $0.05 per share and expiring on December 27, 2021. The Additional Warrants vested at the time of grant.

Going concern The accompanying unaudited interim consolidated condensed financial statements have been prepared assuming the Company will continue as a going concern. As of November 30, 2018, the Company has not achieved profitable operations and has accumulated a deficit of $6,421,823. Continuation as a going concern is dependent upon the ability of the Company to obtain the necessary financing to meet obligations and pay its liabilities arising from normal business operations when they come due and ultimately upon its ability to achieve profitable operations. The outcome of these matters cannot be predicted with any certainty at this time and raises substantial doubt that the Company will be able to continue as a going concern. These financial statements do not include any adjustments to the amounts and classification of assets and liabilities that may be necessary should the Company be unable to continue as a going concern. Management intends to obtain additional funding by borrowing funds from its directors and officers, issuing promissory notes and/or a private placement of common stock.

<table border="0" cellspacing="0" cellpadding="0" width="99%" style='width:99.0%;border-collapse:collapse'> <tr align="left"> <td valign="top" style='border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'>   </td> <td colspan="2" valign="bottom" style='border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'> November 30, 2018 </td> <td valign="bottom" style='border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'>   </td> <td colspan="2" valign="bottom" style='border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'> May 31, 2018 </td> </tr> <tr align="left"> <td valign="top" style='border:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> Due to the former Chief Executive Officer (CEO) and director </td> <td valign="bottom" style='border:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> $ </td> <td valign="bottom" style='border:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 52,626 </td> <td valign="bottom" style='border:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'>   </td> <td valign="bottom" style='border:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> $ </td> <td valign="bottom" style='border:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 54,275 </td> </tr> <tr align="left"> <td valign="top" style='padding:0in 5.4pt 0in 5.4pt'> Due to a director, CEO and President </td> <td valign="bottom" style='padding:0in 5.4pt 0in 5.4pt'>   </td> <td valign="bottom" style='padding:0in 5.4pt 0in 5.4pt'> 54,000 </td> <td valign="bottom" style='padding:0in 5.4pt 0in 5.4pt'>   </td> <td valign="bottom" style='padding:0in 5.4pt 0in 5.4pt'>   </td> <td valign="bottom" style='padding:0in 5.4pt 0in 5.4pt'> 32,400 </td> </tr> <tr align="left"> <td valign="top" style='background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> Due to the Chief Financial Officer (CFO) </td> <td valign="bottom" style='background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'>   </td> <td valign="bottom" style='background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 30,735 </td> <td valign="bottom" style='background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'>   </td> <td valign="bottom" style='background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'>   </td> <td valign="bottom" style='background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 20,790 </td> </tr> <tr align="left"> <td valign="top" style='padding:0in 5.4pt 0in 5.4pt'> Due to the Vice President (VP), Technology and Operations </td> <td valign="bottom" style='padding:0in 5.4pt 0in 5.4pt'>   </td> <td valign="bottom" style='padding:0in 5.4pt 0in 5.4pt'> 54,895 </td> <td valign="bottom" style='padding:0in 5.4pt 0in 5.4pt'>   </td> <td valign="bottom" style='padding:0in 5.4pt 0in 5.4pt'>   </td> <td valign="bottom" style='padding:0in 5.4pt 0in 5.4pt'> 59,035 </td> </tr> <tr align="left"> <td valign="top" style='background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> Due to the former Chief Medical Officer </td> <td valign="bottom" style='background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'>   </td> <td valign="bottom" style='background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 81,059 </td> <td valign="bottom" style='background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'>   </td> <td valign="bottom" style='background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'>   </td> <td valign="bottom" style='background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 81,059 </td> </tr> <tr align="left"> <td valign="top" style='border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> Due to the former VP, Corporate Strategy </td> <td valign="bottom" style='border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td valign="bottom" style='border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> 86,770 </td> <td valign="bottom" style='border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td valign="bottom" style='border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td valign="bottom" style='border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> 86,758 </td> </tr> <tr align="left"> <td valign="top" style='border:none;border-bottom:double windowtext 1.5pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> Due to related parties </td> <td valign="bottom" style='border:none;border-bottom:double windowtext 1.5pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> $ </td> <td valign="bottom" style='border:none;border-bottom:double windowtext 1.5pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 360,085 </td> <td valign="bottom" style='border:none;border-bottom:double windowtext 1.5pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'>   </td> <td valign="bottom" style='border:none;border-bottom:double windowtext 1.5pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> $ </td> <td valign="bottom" style='border:none;border-bottom:double windowtext 1.5pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 334,317 </td> </tr> </table>

<table border="0" cellspacing="0" cellpadding="0" width="98%" style='border-collapse:collapse'> <tr align="left"> <td width="409" valign="top" style='width:306.9pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="101" colspan="2" valign="bottom" style='width:75.65pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0'> November 30, 2018 </td> <td width="16" valign="bottom" style='width:11.9pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="101" colspan="2" valign="bottom" style='width:75.65pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'> November 30, 2017 </td> </tr> <tr align="left"> <td width="409" valign="top" style='width:306.9pt;border:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> Management fees incurred to the CEO </td> <td width="28" valign="bottom" style='width:20.8pt;border:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> $ </td> <td width="73" valign="bottom" style='width:54.85pt;border:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 21,600 </td> <td width="16" valign="bottom" style='width:11.9pt;border:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="28" valign="bottom" style='width:20.8pt;border:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> $ </td> <td width="73" valign="bottom" style='width:54.85pt;border:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 21,600 </td> </tr> <tr align="left"> <td width="409" valign="top" style='width:306.9pt;padding:0in 5.4pt 0in 5.4pt'> Management fees incurred to the CFO </td> <td width="28" valign="bottom" style='width:20.8pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="73" valign="bottom" style='width:54.85pt;padding:0in 5.4pt 0in 5.4pt'> 6,000 </td> <td width="16" valign="bottom" style='width:11.9pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="28" valign="bottom" style='width:20.8pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="73" valign="bottom" style='width:54.85pt;padding:0in 5.4pt 0in 5.4pt'> 6,000 </td> </tr> <tr align="left"> <td width="409" valign="top" style='width:306.9pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> Stock-based compensation incurred to the CFO </td> <td width="28" valign="bottom" style='width:20.8pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="73" valign="bottom" style='width:54.85pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> -- </td> <td width="16" valign="bottom" style='width:11.9pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="28" valign="bottom" style='width:20.8pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="73" valign="bottom" style='width:54.85pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 89,556 </td> </tr> <tr align="left"> <td width="409" valign="top" style='width:306.9pt;padding:0in 5.4pt 0in 5.4pt'> Consulting fees incurred to the VP, Technology and Operations </td> <td width="28" valign="bottom" style='width:20.8pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="73" valign="bottom" style='width:54.85pt;padding:0in 5.4pt 0in 5.4pt'> 25,638 </td> <td width="16" valign="bottom" style='width:11.9pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="28" valign="bottom" style='width:20.8pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="73" valign="bottom" style='width:54.85pt;padding:0in 5.4pt 0in 5.4pt'> 23,475 </td> </tr> <tr align="left"> <td width="409" valign="top" style='width:306.9pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> Stock-based compensation incurred to the Former Chief Medical Officer </td> <td width="28" valign="bottom" style='width:20.8pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="73" valign="bottom" style='width:54.85pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> -- </td> <td width="16" valign="bottom" style='width:11.9pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="28" valign="bottom" style='width:20.8pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="73" valign="bottom" style='width:54.85pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 17,375 </td> </tr> <tr align="left"> <td width="409" valign="top" style='width:306.9pt;padding:0in 5.4pt 0in 5.4pt'> Accrued interest expense incurred to the Companys shareholder (Note 7) </td> <td width="28" valign="bottom" style='width:20.8pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="73" valign="bottom" style='width:54.85pt;padding:0in 5.4pt 0in 5.4pt'> 4,294 </td> <td width="16" valign="bottom" style='width:11.9pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="28" valign="bottom" style='width:20.8pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="73" valign="bottom" style='width:54.85pt;padding:0in 5.4pt 0in 5.4pt'> 3,170 </td> </tr> <tr align="left"> <td width="409" valign="top" style='width:306.9pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:double windowtext 1.5pt;border-right:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> Total transactions with related parties </td> <td width="28" valign="bottom" style='width:20.8pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:double windowtext 1.5pt;border-right:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> $ </td> <td width="73" valign="bottom" style='width:54.85pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:double windowtext 1.5pt;border-right:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 57,532 </td> <td width="16" valign="bottom" style='width:11.9pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:double windowtext 1.5pt;border-right:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="28" valign="bottom" style='width:20.8pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:double windowtext 1.5pt;border-right:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> $ </td> <td width="73" valign="bottom" style='width:54.85pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:double windowtext 1.5pt;border-right:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 161,176 </td> </tr> </table>

<table border="0" cellspacing="0" cellpadding="0" width="76%" style='width:76.84%;border-collapse:collapse'> <tr align="left"> <td valign="top" style='border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="26%" colspan="2" valign="bottom" style='width:26.2%;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'> November 30, 2018 </td> <td valign="bottom" style='border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'>   </td> <td colspan="2" valign="bottom" style='border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'> May 31, 2018 </td> </tr> <tr align="left"> <td valign="top" style='border:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> Book value, beginning of the period </td> <td width="5%" valign="bottom" style='width:5.66%;border:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> $ </td> <td valign="bottom" style='border:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> -- </td> <td valign="bottom" style='border:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'>   </td> <td valign="bottom" style='border:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> $ </td> <td valign="bottom" style='border:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 193,571 </td> </tr> <tr align="left"> <td valign="top" style='padding:0in 5.4pt 0in 5.4pt'> Changes during the period </td> <td width="5%" valign="bottom" style='width:5.66%;padding:0in 5.4pt 0in 5.4pt'>   </td> <td valign="bottom" style='padding:0in 5.4pt 0in 5.4pt'> 1,915 </td> <td valign="bottom" style='padding:0in 5.4pt 0in 5.4pt'>   </td> <td valign="bottom" style='padding:0in 5.4pt 0in 5.4pt'>   </td> <td valign="bottom" style='padding:0in 5.4pt 0in 5.4pt'> (193,571) </td> </tr> <tr align="left"> <td valign="top" style='background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> Amortization </td> <td width="5%" valign="bottom" style='width:5.66%;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'>   </td> <td valign="bottom" style='background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> (110) </td> <td valign="bottom" style='background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'>   </td> <td valign="bottom" style='background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'>   </td> <td valign="bottom" style='background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> -- </td> </tr> <tr align="left"> <td valign="top" style='border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> Foreign exchange </td> <td width="5%" valign="bottom" style='width:5.66%;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td valign="bottom" style='border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> (33) </td> <td valign="bottom" style='border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td valign="bottom" style='border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td valign="bottom" style='border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> -- </td> </tr> <tr align="left"> <td valign="top" style='border:none;border-bottom:double windowtext 1.5pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> Book value, end of the period </td> <td width="5%" valign="bottom" style='width:5.66%;border:none;border-bottom:double windowtext 1.5pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> $ </td> <td valign="bottom" style='border:none;border-bottom:double windowtext 1.5pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 1,772 </td> <td valign="bottom" style='border:none;border-bottom:double windowtext 1.5pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'>   </td> <td valign="bottom" style='border:none;border-bottom:double windowtext 1.5pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> $ </td> <td valign="bottom" style='border:none;border-bottom:double windowtext 1.5pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> -- </td> </tr> </table>

<table border="0" cellspacing="0" cellpadding="0" width="90%" style='border-collapse:collapse'> <tr align="left"> <td width="575" colspan="15" valign="bottom" style='width:430.9pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> As at November 30, 2018 </td> </tr> <tr align="left"> <td width="111" colspan="3" valign="bottom" style='width:82.95pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> Principal Outstanding </td> <td width="104" colspan="2" valign="bottom" style='width:78.0pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> Interest Rate per Annum </td> <td width="160" colspan="3" valign="bottom" style='width:120.25pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="92" colspan="4" valign="bottom" style='width:69.15pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> Accrued Interest </td> <td width="107" colspan="3" valign="bottom" style='width:80.55pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> Total Book Value </td> </tr> <tr align="left"> <td width="34" valign="bottom" style='width:25.55pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> $ </td> <td width="77" colspan="2" valign="bottom" style='width:57.4pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 29,457 </td> <td width="104" colspan="2" valign="bottom" style='width:78.0pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 6% </td> <td width="160" colspan="3" valign="bottom" style='width:120.25pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> Non-convertible </td> <td width="34" colspan="2" valign="bottom" style='width:25.55pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> $ </td> <td width="58" colspan="2" valign="bottom" style='width:43.6pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 716 </td> <td width="34" colspan="2" valign="bottom" style='width:25.55pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> $ </td> <td width="73" valign="bottom" style='width:55.0pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 30,173 </td> </tr> <tr align="left"> <td width="34" valign="bottom" style='width:25.55pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="77" colspan="2" valign="bottom" style='width:57.4pt;padding:0in 5.4pt 0in 5.4pt'> 115,964 </td> <td width="104" colspan="2" valign="bottom" style='width:78.0pt;padding:0in 5.4pt 0in 5.4pt'> 0%-12% </td> <td width="160" colspan="3" valign="bottom" style='width:120.25pt;padding:0in 5.4pt 0in 5.4pt'> Former related party(1) </td> <td width="34" colspan="2" valign="bottom" style='width:25.55pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="58" colspan="2" valign="bottom" style='width:43.6pt;padding:0in 5.4pt 0in 5.4pt'> 8,184 </td> <td width="34" colspan="2" valign="bottom" style='width:25.55pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="73" valign="bottom" style='width:55.0pt;padding:0in 5.4pt 0in 5.4pt'> 124,148 </td> </tr> <tr align="left"> <td width="34" valign="bottom" style='width:25.55pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="77" colspan="2" valign="bottom" style='width:57.4pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 40,050 </td> <td width="104" colspan="2" valign="bottom" style='width:78.0pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 0% </td> <td width="160" colspan="3" valign="bottom" style='width:120.25pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> Advances(2) </td> <td width="34" colspan="2" valign="bottom" style='width:25.55pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="58" colspan="2" valign="bottom" style='width:43.6pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> -- </td> <td width="34" colspan="2" valign="bottom" style='width:25.55pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="73" valign="bottom" style='width:55.0pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 40,050 </td> </tr> <tr align="left"> <td width="34" valign="bottom" style='width:25.55pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:double windowtext 1.5pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'> $ </td> <td width="77" colspan="2" valign="bottom" style='width:57.4pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:double windowtext 1.5pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'> 185,471 </td> <td width="104" colspan="2" valign="bottom" style='width:78.0pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:double windowtext 1.5pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="160" colspan="3" valign="bottom" style='width:120.25pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:double windowtext 1.5pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="34" colspan="2" valign="bottom" style='width:25.55pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:double windowtext 1.5pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'> $ </td> <td width="58" colspan="2" valign="bottom" style='width:43.6pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:double windowtext 1.5pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'> 8,900 </td> <td width="34" colspan="2" valign="bottom" style='width:25.55pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:double windowtext 1.5pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'> $ </td> <td width="73" valign="bottom" style='width:55.0pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:double windowtext 1.5pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'> 194,371 </td> </tr> <tr align="left"> <td width="575" colspan="15" valign="bottom" style='width:430.9pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>   </td> </tr> <tr align="left"> <td width="575" colspan="15" valign="bottom" style='width:430.9pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> As at May 31, 2018 </td> </tr> <tr align="left"> <td width="112" colspan="4" valign="bottom" style='width:84.1pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> Principal Outstanding </td> <td width="105" colspan="2" valign="bottom" style='width:79.05pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> Interest Rate per Annum </td> <td width="155" valign="bottom" style='width:116.0pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="93" colspan="4" valign="bottom" style='width:70.1pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> Accrued Interest </td> <td width="109" colspan="4" valign="bottom" style='width:81.65pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> Total Book Value </td> </tr> <tr align="left"> <td width="35" colspan="2" valign="bottom" style='width:25.95pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> $ </td> <td width="78" colspan="2" valign="bottom" style='width:58.15pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 6,000 </td> <td width="105" colspan="2" valign="bottom" style='width:79.05pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 6% </td> <td width="155" valign="bottom" style='width:116.0pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> Non-convertible </td> <td width="35" colspan="2" valign="bottom" style='width:25.9pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> $ </td> <td width="59" colspan="2" valign="bottom" style='width:44.2pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 225 </td> <td width="35" colspan="2" valign="bottom" style='width:25.9pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> $ </td> <td width="74" colspan="2" valign="bottom" style='width:55.75pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 6,225 </td> </tr> <tr align="left"> <td width="35" colspan="2" valign="bottom" style='width:25.95pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="78" colspan="2" valign="bottom" style='width:58.15pt;padding:0in 5.4pt 0in 5.4pt'> 95,570 </td> <td width="105" colspan="2" valign="bottom" style='width:79.05pt;padding:0in 5.4pt 0in 5.4pt'> 6%-12% </td> <td width="155" valign="bottom" style='width:116.0pt;padding:0in 5.4pt 0in 5.4pt'> Former related party </td> <td width="35" colspan="2" valign="bottom" style='width:25.9pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="59" colspan="2" valign="bottom" style='width:44.2pt;padding:0in 5.4pt 0in 5.4pt'> 4,066 </td> <td width="35" colspan="2" valign="bottom" style='width:25.9pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="74" colspan="2" valign="bottom" style='width:55.75pt;padding:0in 5.4pt 0in 5.4pt'> 99,636 </td> </tr> <tr align="left"> <td width="35" colspan="2" valign="bottom" style='width:25.95pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="78" colspan="2" valign="bottom" style='width:58.15pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 11,598 </td> <td width="105" colspan="2" valign="bottom" style='width:79.05pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 0% </td> <td width="155" valign="bottom" style='width:116.0pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> Advances </td> <td width="35" colspan="2" valign="bottom" style='width:25.9pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="59" colspan="2" valign="bottom" style='width:44.2pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> -- </td> <td width="35" colspan="2" valign="bottom" style='width:25.9pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="74" colspan="2" valign="bottom" style='width:55.75pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 11,598 </td> </tr> <tr align="left"> <td width="35" colspan="2" valign="bottom" style='width:25.95pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:double windowtext 1.5pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'> $ </td> <td width="78" colspan="2" valign="bottom" style='width:58.15pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:double windowtext 1.5pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'> 113,168 </td> <td width="105" colspan="2" valign="bottom" style='width:79.05pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:double windowtext 1.5pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="155" valign="bottom" style='width:116.0pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:double windowtext 1.5pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="35" colspan="2" valign="bottom" style='width:25.9pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:double windowtext 1.5pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'> $ </td> <td width="59" colspan="2" valign="bottom" style='width:44.2pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:double windowtext 1.5pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'> 4,291 </td> <td width="35" colspan="2" valign="bottom" style='width:25.9pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:double windowtext 1.5pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'> $ </td> <td width="74" colspan="2" valign="bottom" style='width:55.75pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:double windowtext 1.5pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'> 117,459 </td> </tr> <tr align="left"> <td width="40" style='border:none'></td> <td width="1" style='border:none'></td> <td width="89" style='border:none'></td> <td width="2" style='border:none'></td> <td width="120" style='border:none'></td> <td width="3" style='border:none'></td> <td width="181" style='border:none'></td> <td width="3" style='border:none'></td> <td width="37" style='border:none'></td> <td width="3" style='border:none'></td> <td width="66" style='border:none'></td> <td width="2" style='border:none'></td> <td width="39" style='border:none'></td> <td width="1" style='border:none'></td> <td width="86" style='border:none'></td> </tr> </table>

<table border="0" cellspacing="0" cellpadding="0" width="98%" style='border-collapse:collapse'> <tr align="left"> <td width="97" valign="bottom" style='width:72.8pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'> Date </td> <td width="73" valign="bottom" style='width:54.4pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'> Principal (CAD$) </td> <td width="60" valign="bottom" style='width:45.05pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'> Interest Rate </td> <td width="257" valign="bottom" style='width:193.05pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'> Additional Terms </td> <td width="66" valign="bottom" style='width:49.6pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'> Accrued Interest (CAD$) </td> <td width="78" valign="bottom" style='width:58.55pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'> Total Book Value (CAD$) </td> </tr> <tr align="left"> <td width="97" valign="top" style='width:72.8pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> June 7, 2018 </td> <td width="73" valign="top" style='width:54.4pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> $10,500 </td> <td width="60" valign="top" style='width:45.05pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 12% </td> <td width="257" valign="top" style='width:193.05pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> Convertible into units of the Companys common stock at $0.10 per unit. Includes CAD$500 finance fee, added to principal. Payable on demand. </td> <td width="66" valign="top" style='width:49.6pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> $622 </td> <td width="78" valign="top" style='width:58.55pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> $11,122 </td> </tr> <tr align="left"> <td width="97" valign="top" style='width:72.8pt;padding:0in 5.4pt 0in 5.4pt'> July 3, 2018 </td> <td width="73" valign="top" style='width:54.4pt;padding:0in 5.4pt 0in 5.4pt'> $10,000 </td> <td width="60" valign="top" style='width:45.05pt;padding:0in 5.4pt 0in 5.4pt'> 0% </td> <td width="257" valign="top" style='width:193.05pt;padding:0in 5.4pt 0in 5.4pt'> Short-term loan payable within 14 days after grant. As at November 30, 2018, the loan has not been repaid and therefore was payable on demand. </td> <td width="66" valign="top" style='width:49.6pt;padding:0in 5.4pt 0in 5.4pt'> -- </td> <td width="78" valign="top" style='width:58.55pt;padding:0in 5.4pt 0in 5.4pt'> 10,000 </td> </tr> <tr align="left"> <td width="97" valign="top" style='width:72.8pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> August 1, 2018 </td> <td width="73" valign="top" style='width:54.4pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> $10,000 </td> <td width="60" valign="top" style='width:45.05pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 12% </td> <td width="257" valign="top" style='width:193.05pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> Convertible into units of the Companys common stock on the terms and at a price of the private placement offering open at the time of conversion. Payable on demand. </td> <td width="66" valign="top" style='width:49.6pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 404 </td> <td width="78" valign="top" style='width:58.55pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 10,404 </td> </tr> <tr align="left"> <td width="97" valign="bottom" style='width:72.8pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:double windowtext 1.5pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="73" valign="top" style='width:54.4pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:double windowtext 1.5pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'> $30,500 </td> <td width="60" valign="bottom" style='width:45.05pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:double windowtext 1.5pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="257" valign="bottom" style='width:193.05pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:double windowtext 1.5pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="66" valign="top" style='width:49.6pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:double windowtext 1.5pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'> $1,026 </td> <td width="78" valign="top" style='width:58.55pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:double windowtext 1.5pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'> $31,526 </td> </tr> </table>

<table border="0" cellspacing="0" cellpadding="0" width="99%" style='border-collapse:collapse'> <tr align="left"> <td width="223" valign="top" style='width:167.6pt;border:none;border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="198" colspan="3" valign="bottom" style='width:148.5pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'> Six months ended November 30, 2018 </td> <td width="20" valign="bottom" style='width:15.1pt;border:none;border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="190" colspan="3" valign="bottom" style='width:142.8pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'> Year ended May 31, 2018 </td> </tr> <tr align="left"> <td width="223" valign="top" style='width:167.6pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="96" valign="bottom" style='width:71.75pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> Number of options </td> <td width="102" colspan="2" valign="bottom" style='width:76.75pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'> Weighted average exercise price </td> <td width="20" valign="bottom" style='width:15.1pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="86" valign="bottom" style='width:64.7pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> Number of options </td> <td width="104" colspan="2" valign="bottom" style='width:78.1pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'> Weighted average exercise price </td> </tr> <tr align="left"> <td width="223" valign="top" style='width:167.6pt;border:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> Options outstanding, beginning </td> <td width="96" valign="bottom" style='width:71.75pt;border:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 9,450,000 </td> <td width="44" valign="bottom" style='width:33.2pt;border:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> $ </td> <td width="58" valign="bottom" style='width:43.55pt;border:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 0.35 </td> <td width="20" valign="bottom" style='width:15.1pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="86" valign="bottom" style='width:64.7pt;border:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 7,550,000 </td> <td width="46" valign="bottom" style='width:34.55pt;border:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> $ </td> <td width="58" valign="bottom" style='width:43.55pt;border:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 0.35 </td> </tr> <tr align="left"> <td width="223" valign="top" style='width:167.6pt;padding:0in 5.4pt 0in 5.4pt'> Options granted </td> <td width="96" valign="bottom" style='width:71.75pt;padding:0in 5.4pt 0in 5.4pt'> -- </td> <td width="44" valign="bottom" style='width:33.2pt;padding:0in 5.4pt 0in 5.4pt'> $ </td> <td width="58" valign="bottom" style='width:43.55pt;padding:0in 5.4pt 0in 5.4pt'> n/a </td> <td width="20" valign="bottom" style='width:15.1pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="86" valign="bottom" style='width:64.7pt;padding:0in 5.4pt 0in 5.4pt'> 2,050,000 </td> <td width="46" valign="bottom" style='width:34.55pt;padding:0in 5.4pt 0in 5.4pt'> $ </td> <td width="58" valign="bottom" style='width:43.55pt;padding:0in 5.4pt 0in 5.4pt'> 0.35 </td> </tr> <tr align="left"> <td width="223" valign="top" style='width:167.6pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> Options expired </td> <td width="96" valign="bottom" style='width:71.75pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> -- </td> <td width="44" valign="bottom" style='width:33.2pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> $ </td> <td width="58" valign="bottom" style='width:43.55pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> n/a </td> <td width="20" valign="bottom" style='width:15.1pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="86" valign="bottom" style='width:64.7pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> (150,000) </td> <td width="46" valign="bottom" style='width:34.55pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> $ </td> <td width="58" valign="bottom" style='width:43.55pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 0.20 </td> </tr> <tr align="left"> <td width="223" valign="top" style='width:167.6pt;padding:0in 5.4pt 0in 5.4pt'> Options cancelled </td> <td width="96" valign="bottom" style='width:71.75pt;padding:0in 5.4pt 0in 5.4pt'> (2,400,000) </td> <td width="44" valign="bottom" style='width:33.2pt;padding:0in 5.4pt 0in 5.4pt'> $ </td> <td width="58" valign="bottom" style='width:43.55pt;padding:0in 5.4pt 0in 5.4pt'> 0.67 </td> <td width="20" valign="bottom" style='width:15.1pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="86" valign="bottom" style='width:64.7pt;padding:0in 5.4pt 0in 5.4pt'> -- </td> <td width="46" valign="bottom" style='width:34.55pt;padding:0in 5.4pt 0in 5.4pt'> $ </td> <td width="58" valign="bottom" style='width:43.55pt;padding:0in 5.4pt 0in 5.4pt'> n/a </td> </tr> <tr align="left"> <td width="223" valign="top" style='width:167.6pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:double windowtext 1.5pt;border-right:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> Options outstanding, ending </td> <td width="96" valign="bottom" style='width:71.75pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:double windowtext 1.5pt;border-right:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 7,050,000 </td> <td width="44" valign="bottom" style='width:33.2pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:double windowtext 1.5pt;border-right:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> $ </td> <td width="58" valign="bottom" style='width:43.55pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:double windowtext 1.5pt;border-right:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 0.24 </td> <td width="20" valign="bottom" style='width:15.1pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="86" valign="bottom" style='width:64.7pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:double windowtext 1.5pt;border-right:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 9,450,000 </td> <td width="46" valign="bottom" style='width:34.55pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:double windowtext 1.5pt;border-right:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> $ </td> <td width="58" valign="bottom" style='width:43.55pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:double windowtext 1.5pt;border-right:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 0.35 </td> </tr> </table>

<table border="1" cellspacing="0" cellpadding="0" width="81%" style='border-collapse:collapse;border:none'> <tr align="left"> <td width="237" valign="top" style='width:177.8pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="136" valign="bottom" style='width:102.1pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'> Six months ended November 30, 2018 </td> <td width="23" valign="bottom" style='width:17.35pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="125" valign="bottom" style='width:93.95pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'> Year ended May 31, 2018 </td> </tr> <tr align="left"> <td width="237" valign="top" style='width:177.8pt;border:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> Warrants outstanding, beginning </td> <td width="136" valign="bottom" style='width:102.1pt;border:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 12,814,605 </td> <td width="23" valign="bottom" style='width:17.35pt;border:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="125" valign="bottom" style='width:93.95pt;border:none;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 11,094,605 </td> </tr> <tr align="left"> <td width="237" valign="top" style='width:177.8pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> Warrants issued </td> <td width="136" valign="bottom" style='width:102.1pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> -- </td> <td width="23" valign="bottom" style='width:17.35pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="125" valign="bottom" style='width:93.95pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> 1,720,000 </td> </tr> <tr align="left"> <td width="237" valign="top" style='width:177.8pt;border:none;border-bottom:double windowtext 1.5pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> Warrants outstanding, ending </td> <td width="136" valign="bottom" style='width:102.1pt;border:none;border-bottom:double windowtext 1.5pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 12,814,605 </td> <td width="23" valign="bottom" style='width:17.35pt;border:none;border-bottom:double windowtext 1.5pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="125" valign="bottom" style='width:93.95pt;border:none;border-bottom:double windowtext 1.5pt;background:#DBE5F1;padding:0in 5.4pt 0in 5.4pt'> 12,814,605 </td> </tr> </table>

-6421823

52626

54275

54000

32400

30735

20790

54895

59035

81059

86770

86758

360085

334317

21600

6000

89556

25638

23475

17375

4294

3170

57532

161176

13694

10793

46093

2572

23915

6644

2351

193571

1915

-193571

110

-33

1772

301277

51585

250000

29457

0.0600

716

30173

115964

0.1200

8184

124148

40050

185471

8900

194371

6000

0.0600

225

6225

95570

0.1200

4066

99636

11598

113168

4291

117459

23029

28871

4790

8241

7550000

0.35

-2400000

7050000

0.24

9450000

0.35

0.05

2500000

0.35

2500000

0.35

2050000

11094605

1720000

12814605

2000000 9094605 1480000 240000 12814605

250000

100000

5000000 2482960 10-Q 2018-11-30 false Cell MedX Corp. 0001493712 cmxc --05-31 44282749 Smaller Reporting Company Yes 2019 Q2 0001493712 2018-06-01 2018-11-30 0001493712 2019-01-14 0001493712 2018-11-30 0001493712 2018-05-31 0001493712 2018-09-01 2018-11-30 0001493712 2017-09-01 2017-11-30 0001493712 2017-06-01 2017-11-30 0001493712 2017-12-01 2018-05-31 0001493712 us-gaap:CommonStockMember 2017-06-01 2017-11-30 0001493712 us-gaap:AdditionalPaidInCapitalMember 2017-06-01 2017-11-30 0001493712 us-gaap:RetainedEarningsMember 2017-06-01 2017-11-30 0001493712 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-06-01 2017-11-30 0001493712 us-gaap:CommonStockMember 2017-05-31 0001493712 us-gaap:AdditionalPaidInCapitalMember 2017-05-31 0001493712 us-gaap:RetainedEarningsMember 2017-05-31 0001493712 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-05-31 0001493712 2017-05-31 0001493712 us-gaap:CommonStockMember 2017-11-30 0001493712 us-gaap:AdditionalPaidInCapitalMember 2017-11-30 0001493712 us-gaap:RetainedEarningsMember 2017-11-30 0001493712 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-11-30 0001493712 2017-11-30 0001493712 us-gaap:CommonStockMember 2017-12-01 2018-05-31 0001493712 us-gaap:AdditionalPaidInCapitalMember 2017-12-01 2018-05-31 0001493712 us-gaap:ReserveForOffBalanceSheetActivitiesMember 2017-12-01 2018-05-31 0001493712 us-gaap:RetainedEarningsMember 2017-12-01 2018-05-31 0001493712 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-01 2018-05-31 0001493712 us-gaap:CommonStockMember 2018-05-31 0001493712 us-gaap:AdditionalPaidInCapitalMember 2018-05-31 0001493712 us-gaap:ReserveForOffBalanceSheetActivitiesMember 2018-05-31 0001493712 us-gaap:RetainedEarningsMember 2018-05-31 0001493712 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-05-31 0001493712 us-gaap:RetainedEarningsMember 2018-06-01 2018-11-30 0001493712 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-06-01 2018-11-30 0001493712 us-gaap:CommonStockMember 2018-11-30 0001493712 us-gaap:AdditionalPaidInCapitalMember 2018-11-30 0001493712 us-gaap:ReserveForOffBalanceSheetActivitiesMember 2018-11-30 0001493712 us-gaap:RetainedEarningsMember 2018-11-30 0001493712 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-11-30 0001493712 fil:ForConsultingFeesMember 2017-06-01 2017-11-30 0001493712 fil:DueToTheFormerCeoAndDirectorMember 2018-11-30 0001493712 fil:DueToTheFormerCeoAndDirectorMember 2018-05-31 0001493712 fil:DueToADirectorAndFormerCeoAndPresidentMember 2018-11-30 0001493712 fil:DueToADirectorAndFormerCeoAndPresidentMember 2018-05-31 0001493712 fil:DueToTheCFOMember 2018-11-30 0001493712 fil:DueToTheCFOMember 2018-05-31 0001493712 fil:DueToTheVpOfTechnologyAndOperationsMember 2018-11-30 0001493712 fil:DueToTheVpOfTechnologyAndOperationsMember 2018-05-31 0001493712 fil:DueToTheChiefMedicalOfficerMember 2018-11-30 0001493712 fil:DueToTheChiefMedicalOfficerMember 2018-05-31 0001493712 fil:DueToTheFormerVpCorporateStrategyMember 2018-11-30 0001493712 fil:DueToTheFormerVpCorporateStrategyMember 2018-05-31 0001493712 fil:ManagementFeesIncurredToTheCeoMember 2018-06-01 2018-11-30 0001493712 fil:ManagementFeesIncurredToTheCeoMember 2017-06-01 2017-11-30 0001493712 fil:ManagementFeesIncurredToTheCfoMember 2018-06-01 2018-11-30 0001493712 fil:ManagementFeesIncurredToTheCfoMember 2017-06-01 2017-11-30 0001493712 fil:StockBasedCompensationIncurredToTheCfoMember 2017-06-01 2017-11-30 0001493712 fil:ConsultingFeesIncurredToTheVpTechnologyAndOperationsMember 2018-06-01 2018-11-30 0001493712 fil:ConsultingFeesIncurredToTheVpTechnologyAndOperationsMember 2017-06-01 2017-11-30 0001493712 fil:StockBasedCompensationIncurredToTheChiefMedicalOfficerMember 2017-06-01 2017-11-30 0001493712 fil:AccruedInterestExpenseIncurredToASignificantShareholderMember 2018-06-01 2018-11-30 0001493712 fil:AccruedInterestExpenseIncurredToASignificantShareholderMember 2017-06-01 2017-11-30 0001493712 fil:SuppliesHeldForResaleMember 2018-11-30 0001493712 fil:SuppliesHeldForResaleMember 2018-05-31 0001493712 fil:WorkInProgressWasAssociatedWithEbalanceDevicesMember 2018-11-30 0001493712 fil:PrepaidExpenseMember 2018-11-30 0001493712 fil:PrepaidExpenseMember 2018-05-31 0001493712 fil:ReceivablesAssociatedWithGstMember 2018-11-30 0001493712 fil:ReceivablesAssociatedWithGstMember 2018-05-31 0001493712 2017-06-01 2018-05-31 0001493712 fil:LoiRefundableDepositForExclusiveWorldwideDistributionRightsMember 2018-11-30 0001493712 fil:ShortTermLoan1Member 2018-11-30 0001493712 fil:ShortTermLoan2Member 2018-11-30 0001493712 fil:ShortTermLoan4Member 2018-11-30 0001493712 fil:ShortTermLoan1Member 2018-05-31 0001493712 fil:ShortTermLoan2Member 2018-05-31 0001493712 fil:ShortTermLoan4Member 2018-05-31 0001493712 fil:LoanAgreementsMrJeffsMember 2018-06-01 2018-11-30 0001493712 fil:GrantedNovember252014Member 2014-06-01 2015-05-31 0001493712 fil:OptionsGrantedAugust52015Member 2015-06-01 2016-05-31 0001493712 fil:OptionsGrantedAugust242017CfoAndConsultantsMember 2017-06-01 2018-05-31 0001493712 fil:WarrantsGrantedMarch32016Member 2018-11-30 0001493712 fil:WarrantsExpiringOctober122021Member 2018-11-30 0001493712 fil:WarrantsGrantedOctober122017Member 2018-11-30 0001493712 fil:WarrantsGrantedFebruary72018Member 2018-11-30 0001493712 fil:CreditLineAgreementWithMrJeffsMember 2018-12-20 0001493712 fil:CreditLineAgreementWithMrJeffsMember 2018-12-02 2018-12-20 0001493712 fil:LoanAgreementWithMrJeffsMember 2018-12-02 2018-12-20 xbrli:shares iso4217:USD iso4217:USD shares pure EX-101.SCH 8 cmxc-20181130.xsd 000150 - Disclosure - Share Capital Disclosure link:presentationLink link:definitionLink link:calculationLink 000330 - Disclosure - Unearned Revenue Disclosure (Details) link:presentationLink link:definitionLink link:calculationLink 000090 - Disclosure - Related Party Transactions Disclosure link:presentationLink link:definitionLink link:calculationLink 000110 - Disclosure - Other Current Assets Disclosure link:presentationLink link:definitionLink link:calculationLink 000310 - Disclosure - Other Current Assets Disclosure (Details) link:presentationLink link:definitionLink link:calculationLink 000040 - Statement - Consolidated Statements of Operations link:presentationLink link:definitionLink link:calculationLink 000360 - Disclosure - Share Capital Disclosure: Schedule of Stock Option Activity (Details) link:presentationLink link:definitionLink link:calculationLink 000190 - Disclosure - Related Party Transactions Disclosure: Schedule of Transactions with Related Parties (Tables) link:presentationLink link:definitionLink link:calculationLink 000280 - Disclosure - Related Party Transactions Disclosure: Schedule of Amounts Due to Related Parties (Details) link:presentationLink link:definitionLink link:calculationLink 000080 - Disclosure - Organization and Nature of Operations link:presentationLink link:definitionLink link:calculationLink 000020 - Statement - Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 000370 - Disclosure - Share Capital Disclosure: Schedule of Stock Options Outstanding (Details) link:presentationLink link:definitionLink link:calculationLink 000290 - Disclosure - Related Party Transactions Disclosure: Schedule of Transactions with Related Parties (Details) link:presentationLink link:definitionLink link:calculationLink 000200 - Disclosure - Equipment Disclosure: Amortization schedule for the equipment (Tables) link:presentationLink link:definitionLink link:calculationLink 000300 - Disclosure - Inventory Disclosure (Details) link:presentationLink link:definitionLink link:calculationLink 000140 - Disclosure - Notes and Advances Payable Disclosure link:presentationLink link:definitionLink link:calculationLink 000120 - Disclosure - Equipment Disclosure link:presentationLink link:definitionLink link:calculationLink 000070 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 000380 - Disclosure - Share Capital Disclosure: Schedule of Warrant Activity (Details) link:presentationLink link:definitionLink link:calculationLink 000230 - Disclosure - Share Capital Disclosure: Schedule of Stock Option Activity (Tables) link:presentationLink link:definitionLink link:calculationLink 000170 - Disclosure - Organization and Nature of Operations: Going Concern (Policies) link:presentationLink link:definitionLink link:calculationLink 000180 - Disclosure - Related Party Transactions Disclosure: Schedule of Amounts Due to Related Parties (Tables) link:presentationLink link:definitionLink link:calculationLink 000400 - Disclosure - Subsequent Event Disclosure (Details) link:presentationLink link:definitionLink link:calculationLink 000160 - Disclosure - Subsequent Event Disclosure link:presentationLink link:definitionLink link:calculationLink 000130 - Disclosure - Unearned Revenue Disclosure link:presentationLink link:definitionLink link:calculationLink 000250 - Disclosure - Share Capital Disclosure: Schedule of Warrant Activity (Tables) link:presentationLink link:definitionLink link:calculationLink 000050 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) link:presentationLink link:definitionLink link:calculationLink 000100 - Disclosure - Inventory Disclosure link:presentationLink link:definitionLink link:calculationLink 000260 - Disclosure - Share Capital Disclosure: Schedule of Warrant Details (Tables) link:presentationLink link:definitionLink link:calculationLink 000240 - Disclosure - Share Capital Disclosure: Schedule of Stock Options Outstanding (Tables) link:presentationLink link:definitionLink link:calculationLink 000010 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 000060 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 000350 - Disclosure - Notes and Advances Payable Disclosure (Details) link:presentationLink link:definitionLink link:calculationLink 000320 - Disclosure - Equipment Disclosure: Amortization schedule for the equipment (Details) link:presentationLink link:definitionLink link:calculationLink 000270 - Disclosure - Organization and Nature of Operations: Going Concern (Details) link:presentationLink link:definitionLink link:calculationLink 000030 - Statement - Balance Sheets (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 000340 - Disclosure - Notes and Advances Payable Disclosure: Schedule of Short-term Loans and Advances Outstanding (Details) link:presentationLink link:definitionLink link:calculationLink 000390 - Disclosure - Share Capital Disclosure: Schedule of Warrant Details (Details) link:presentationLink link:definitionLink link:calculationLink 000220 - Disclosure - Notes and Advances Payable Disclosure: Schedule of Former Related Party Loans Payable (Tables) link:presentationLink link:definitionLink link:calculationLink 000210 - Disclosure - Notes and Advances Payable Disclosure: Schedule of Short-term Loans and Advances Outstanding (Tables) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 9 cmxc-20181130_cal.xml EX-101.DEF 10 cmxc-20181130_def.xml EX-101.LAB 11 cmxc-20181130_lab.xml Stock options granted Short-term Debt, Type [Axis] Stock-based compensation incurred to the Chief Medical Officer Schedule of Stock Option Activity Schedule of Transactions with Related Parties Tabular disclosure Notes Advances repaid Units issued on conversion of deposits, shares Represents the Units issued on conversion of deposits, shares (number of shares), during the indicated time period. Accumulated Deficit Other items General and administrative expense Common stock, par value Unsecured Line of Credit, Agreement amount Non-convertible loan Deferred Revenue {1} Deferred Revenue Prepaid expense Schedule of Former Related Party Loans Payable Schedule of Amounts Due to Related Parties Adjustments to reconcile net loss to net cash used in operating activities: Statement [Line Items] Equity Component Sales Accumulated deficit Accumulated deficit Accumulated deficit Accounts payable Cash Proceeds from Lines of Credit Warrants granted October 12, 2017 Work in progress was associated with eBalance devices Transactions with related parties Due to the Chief Medical Officer Schedule of Short-term Loans and Advances Outstanding Common Stock Weighted average number of shares outstanding - basic and diluted Net income (loss) per common share - basic and diluted Gross margin STOCKHOLDERS' DEFICIT Inventory Warrants granted October 12, 2016 Fair Value by Shareholders' Equity Class Options cancelled Asset Class Asset Class [Axis] Due to related parties {2} Due to related parties Schedule of Warrant Activity Tabular disclosure Net increase (decrease) in cash Due to related parties {1} Due to related parties Statement, Equity Components [Axis] Operating expenses Total liabilities and stockholders' deficit Total liabilities and stockholders' deficit Common stock value Current assets Entity Registrant Name Effective interest rate Increase (decrease) in equipment Increase (decrease) in equipment Stock-based compensation incurred to the CFO Related Party [Axis] Other Current Assets Disclosure Accounts payable {1} Accounts payable Other current assets {1} Other current assets Research and development - noncash Amount of expense or loss included in net income that result in no cash flow, financing fees. For Consulting Fees Unrealized foreign exchange translation gain (loss) Gain (loss) on debt settlement Income Statement Current Fiscal Year End Date Subsequent Event Type Accrued interest expense incurred to a shareholder Schedule of Stock Options Outstanding Unearned Revenue Disclosure Related Party Transactions Disclosure Organization and Nature of Operations Effects of foreign currency exchange Units issued on conversion of deposits, value Shares issued Additional Paid-in Capital Comprehensive loss Total operating expenses Total assets Entity Current Reporting Status Number of warrants outstanding Accrued interest/accretion Principal outstanding Former Related Party, loan Receivables associated with GST Proceeds from notes payable Advances received Cash Flows from Financing Activities Accrued liabilities {1} Accrued liabilities Cash Flows from Operating Activities Shares issued for debt, value Beginning Balance, shares Beginning Balance, shares Ending Balance, shares Accumulated Other Comprehensive Income Research and development Common stock, shares outstanding Total stockholders' deficit Total stockholders' deficit Beginning Balance, amount Ending Balance, amount Total Liabilities Total Liabilities Warrants granted February 7, 2018 Due to the former VP of Corporate Strategy Equipment Disclosure Shares issued for cash, shares Reserve Revenue Unearned revenue Due to related parties LIABILITIES AND STOCKHOLDERS' DEFICIT Other current assets Warrants issued Issuance of warrants to acquire common stock Deferred Revenue Arrangement Type [Axis] Supplies held for resale Tables/Schedules Subsequent Event Disclosure Cash Flows from Investing Activities Class of Stock Class of Stock [Axis] Interest expense Accumulated other comprehensive income (loss) Accumulated other comprehensive income (loss) Total current assets Total current assets Entity Central Index Key Document Period End Date Document Type Document and Entity Information Shareholders' Equity Class [Axis] Management fees incurred to the CEO Due to the CFO Cash, beginning of period Cash, beginning of period Cash, end of period Statement of Cash Flows Stock-based compensation Consulting fees Equipment Equipment, book value ASSETS Amendment Flag Options granted November 25, 2014 (Vendors for Technology) Options outsanding, weighted average exercise price Due to the former CEO and Director Non-cash investing transactions: Net cash provided by financing activities Net cash provided by financing activities Proceeds from subscription to shares Consulting fees - noncash Common stock, shares authorized Additional paid-in capital Total current liabilities Total current liabilities Entity Filer Category Loan Agreement with Mr. Jeffs Exercise price (options) Exercise price (options) Advances Policies Unrealized foreign exchange Accretion expense {1} Accretion expense Translation to reporting currency Document Fiscal Year Focus Entity Common Stock, Shares Outstanding Credit Line Agreement with Mr. Jeffs Consulting fees incurred to the VP of Technology and Operations Schedule of Warrant Details Amortization schedule for the equipment Statement of Stockholders' Equity - Parenthetical Shares issued for cash, value Cost of goods sold Reserves Represents the monetary amount of Reserves, as of the indicated date. Accrued liabilities Statement of Financial Position Number of warrants exercisable Number of warrants exercisable Warrants granted March 3, 2016 Options granted August 24, 2017 (CFO and Consultants) Inventory {2} Inventory Inventory [Axis] Management fees incurred to the CFO Going Concern Notes and Advances Payable Disclosure Amortization {1} Amortization Common stock, shares issued Notes and advances payable Current liabilities Stock options outstanding LOI - Refundable deposit for exclusive worldwide distribution rights Due to the VP of Technology and Operations Related Party Share Capital Disclosure Net cash flows used in operating activities Unearned revenue {1} Unearned revenue Inventory {1} Inventory Stock-based compensation {1} Stock-based compensation Accrued interest Net income (loss) {1} Net income (loss) Accretion expense Balance Sheet Trading Symbol Subsequent Event Type [Axis] Options granted August 5, 2015 (CEO, President and a member of the board) Foreign exchange gain (loss), equipment Foreign exchange gain (loss), equipment Due to a Director and former CEO and President Details Inventory Disclosure Settlement of debt with shares EX-101.PRE 12 cmxc-20181130_pre.xml XML 13 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Nov. 30, 2018	Jan. 14, 2019
Document and Entity Information
Entity Registrant Name	Cell MedX Corp.
Document Type	10-Q
Document Period End Date	Nov. 30, 2018
Amendment Flag	false
Entity Central Index Key	0001493712
Current Fiscal Year End Date	--05-31
Entity Common Stock, Shares Outstanding		44,282,749
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q2
Trading Symbol	cmxc

XML 14 R2.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets - USD ($)	Nov. 30, 2018	May 31, 2018
Current assets
Cash	$ 24,377	$ 8,200
Inventory	59,787	10,793
Other current assets	9,216	26,266
Total current assets	93,380	45,259
Equipment	1,772
Total assets	95,152	45,259
Current liabilities
Accounts payable	668,980	594,716
Accrued liabilities	7,493	20,600
Due to related parties	360,085	334,317
Notes and advances payable	194,371	117,459
Unearned revenue	301,277	51,585
Total current liabilities	1,532,206	1,118,677
Total Liabilities	1,532,206	1,118,677
STOCKHOLDERS' DEFICIT
Common stock value	44,283	44,283
Additional paid-in capital	4,916,201	4,916,201
Reserves	14,400	14,400
Accumulated deficit	(6,421,823)	(6,050,841)
Accumulated other comprehensive income (loss)	9,885	2,539
Total stockholders' deficit	(1,437,054)	(1,073,418)
Total liabilities and stockholders' deficit	$ 95,152	$ 45,259

XML 15 R3.htm IDEA: XBRL DOCUMENT

Balance Sheets (Parenthetical) - $ / shares	Nov. 30, 2018	May 31, 2018
Balance Sheet
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	44,282,749	44,282,749
Common stock, shares outstanding	44,282,749	44,282,749

XML 16 R4.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Operations - USD ($)	3 Months Ended		6 Months Ended
Consolidated Statements of Operations - USD ($)	Nov. 30, 2018	Nov. 30, 2017	Nov. 30, 2018	Nov. 30, 2017
Operating expenses
Amortization	$ 110	$ 38,434	$ 110	$ 77,557
Consulting fees	66,678	61,422	130,638	644,881
General and administrative expense	24,448	33,586	52,077	88,061
Research and development	33,633	41,491	183,367	88,994
Stock-based compensation		6,130		106,931
Total operating expenses	124,869	181,063	366,192	1,006,424
Other items
Interest expense	2,648	327	4,790	8,241
Net income (loss)	(127,517)	(181,390)	(370,982)	(1,014,665)
Unrealized foreign exchange translation gain (loss)	6,477	1,464	7,346	(170)
Comprehensive loss	$ (121,040)	$ (179,926)	$ (363,636)	$ (1,014,835)
Net income (loss) per common share - basic and diluted	$ 0	$ 0	$ (0.01)	$ (0.02)
Weighted average number of shares outstanding - basic and diluted	44,282,749	41,997,595	44,282,749	41,116,310

XML 17 R5.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)	Common Stock	Additional Paid-in Capital	Reserve	Accumulated Deficit	Accumulated Other Comprehensive Income	Total
Beginning Balance, shares at May. 31, 2017	40,244,605
Beginning Balance, amount at May. 31, 2017	$ 40,245	$ 3,294,224		$ (4,504,043)	$ 247	$ (1,169,327)
Stock-based compensation		106,931				106,931
Options issued, value		522,407				522,407
Shares issued for cash, shares	1,480,000
Shares issued for cash, value	$ 1,480	368,520				370,000
Shares issued for debt, shares	2,318,144
Shares issued for debt, value	$ 2,318	577,218				579,536
Translation to reporting currency					(170)	(170)
Net income (loss) for the period				(1,014,665)		(1,014,665)
Ending Balance, shares at Nov. 30, 2017	44,042,749
Ending Balance, amount at Nov. 30, 2017	$ 44,043	4,869,300		(5,518,708)	77	(605,288)
Stock-based compensation		1,541				1,541
Units issued on conversion of deposits, shares	240,000
Units issued on conversion of deposits, value	$ 240	45,360	$ 14,400			60,000
Translation to reporting currency					2,462	2,462
Net income (loss) for the period				(532,133)		(532,133)
Ending Balance, shares at May. 31, 2018	44,282,749
Ending Balance, amount at May. 31, 2018	$ 44,283	4,916,201	14,400	(6,050,841)	2,539	(1,073,418)
Translation to reporting currency					7,346	7,346
Net income (loss) for the period				(370,982)		(370,982)
Ending Balance, shares at Nov. 30, 2018	44,282,749
Ending Balance, amount at Nov. 30, 2018	$ 44,283	$ 4,916,201	$ 14,400	$ (6,421,823)	$ 9,885	$ (1,437,054)

XML 18 R6.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Stockholders' Equity (Parenthetical)	6 Months Ended
	Nov. 30, 2017 USD ($)
Options issued, value	$ 522,407
For Consulting Fees
Options issued, value	$ 522,407

XML 19 R7.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Cash Flows - USD ($)	6 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Nov. 30, 2018	Nov. 30, 2017
Cash Flows from Operating Activities
Net income (loss)	$ (370,982)	$ (1,014,665)
Adjustments to reconcile net loss to net cash used in operating activities:
Accrued interest	4,790	8,241
Amortization	110	77,557
Consulting fees - noncash		522,407
Financing fees - noncash	387
Unrealized foreign exchange	(2,788)	5,127
Stock-based compensation		106,931
Changes to operating assets and liabilities:
Inventory	(50,072)	(21,133)
Other current assets	16,823	(99,028)
Accounts payable	75,053	66,244
Accrued liabilities	(13,107)	(74,719)
Unearned revenue	250,000	59,588
Due to related parties	26,352	30,246
Net cash flows used in operating activities	(63,434)	(333,204)
Cash Flows from Investing Activities
Acquisition of equipment	1,915
Net cash used by investing activities	(1,915)
Cash Flows from Financing Activities
Advances repaid		22,704
Advances received	28,871
Proceeds from notes payable	47,004	25,318
Proceeds from subscription to shares		370,000
Net cash provided by financing activities	75,875	372,614
Effects of foreign currency exchange	5,651	1,464
Net increase (decrease) in cash	16,177	40,874
Cash, beginning of period	8,200	67,494
Cash, end of period	$ 24,377	108,368
Non-cash investing transactions:
Settlement of debt with shares		$ 579,536

XML 20 R8.htm IDEA: XBRL DOCUMENT

Organization and Nature of Operations

6 Months Ended

Nov. 30, 2018

Notes

Organization and Nature of Operations

NOTE 1 - ORGANIZATION AND NATURE OF OPERATIONS

Unaudited Interim Financial Statements

Going concern

XML 21 R9.htm IDEA: XBRL DOCUMENT

Related Party Transactions Disclosure

6 Months Ended

Nov. 30, 2018

Notes

Related Party Transactions Disclosure

NOTE 2 - RELATED PARTY TRANSACTIONS

Amounts due to related parties, other than notes payable to related parties (Note 7) at November 30, 2018 and May 31, 2018:

	November 30, 2018		May 31, 2018
Due to the former Chief Executive Officer (“CEO”) and director	$	52,626	$	54,275
Due to a director, CEO and President		54,000		32,400
Due to the Chief Financial Officer (“CFO”)		30,735		20,790
Due to the Vice President (“VP”), Technology and Operations		54,895		59,035
Due to the former Chief Medical Officer		81,059		81,059
Due to the former VP, Corporate Strategy		86,770		86,758
Due to related parties	$	360,085	$	334,317

These amounts are unsecured, due on demand and bear no interest.

During the six-month periods ended November 30, 2018 and 2017, the Company had the following transactions with related parties:

	November 30, 2018		November 30, 2017
Management fees incurred to the CEO	$	21,600	$	21,600
Management fees incurred to the CFO		6,000		6,000
Stock-based compensation incurred to the CFO		--		89,556
Consulting fees incurred to the VP, Technology and Operations		25,638		23,475
Stock-based compensation incurred to the Former Chief Medical Officer		--		17,375
Accrued interest expense incurred to the Company’s shareholder (Note 7)		4,294		3,170
Total transactions with related parties	$	57,532	$	161,176

XML 22 R10.htm IDEA: XBRL DOCUMENT

Inventory Disclosure

6 Months Ended

Nov. 30, 2018

Notes

Inventory Disclosure

NOTE 3 - INVENTORY

XML 23 R11.htm IDEA: XBRL DOCUMENT

Other Current Assets Disclosure

6 Months Ended

Nov. 30, 2018

Notes

Other Current Assets Disclosure

NOTE 4 - OTHER CURRENT ASSETS

XML 24 R12.htm IDEA: XBRL DOCUMENT

Equipment Disclosure

6 Months Ended

Nov. 30, 2018

Notes

Equipment Disclosure

NOTE 5 - EQUIPMENT

Amortization schedule for the equipment at November 30, 2018 and May 31, 2018:

	November 30, 2018		May 31, 2018
Book value, beginning of the period	$	--	$	193,571
Changes during the period		1,915		(193,571)
Amortization		(110)		--
Foreign exchange		(33)		--
Book value, end of the period	$	1,772	$	--

XML 25 R13.htm IDEA: XBRL DOCUMENT

Unearned Revenue Disclosure

6 Months Ended

Nov. 30, 2018

Notes

Unearned Revenue Disclosure

NOTE 6 - UNEARNED REVENUE

XML 26 R14.htm IDEA: XBRL DOCUMENT

Notes and Advances Payable Disclosure

6 Months Ended

Nov. 30, 2018

Notes

Notes and Advances Payable Disclosure

NOTE 7 - NOTES AND ADVANCES PAYABLE

The tables below summarize the short-term loans and advances outstanding as at November 30, 2018 and May 31, 2018:

As at November 30, 2018
Principal Outstanding			Interest Rate per Annum					Accrued Interest				Total Book Value
$	29,457		6%		Non-convertible			$		716		$		30,173
	115,964		0%-12%		Former related party⁽¹⁾					8,184				124,148
	40,050		0%		Advances⁽²⁾					--				40,050
$	185,471							$		8,900		$		194,371

As at May 31, 2018
Principal Outstanding				Interest Rate per Annum			Accrued Interest				Total Book Value
$		6,000		6%		Non-convertible	$		225		$		6,225
		95,570		6%-12%		Former related party			4,066				99,636
		11,598		0%		Advances			--				11,598
$		113,168					$		4,291		$		117,459

(1) Former Related Party Loans Payable

Date	Principal (CAD$)	Interest Rate	Additional Terms	Accrued Interest (CAD$)	Total Book Value (CAD$)
June 7, 2018	$10,500	12%	Convertible into units of the Company’s common stock at $0.10 per unit. Includes CAD$500 finance fee, added to principal. Payable on demand.	$622	$11,122
July 3, 2018	$10,000	0%	Short-term loan payable within 14 days after grant. As at November 30, 2018, the loan has not been repaid and therefore was payable on demand.	--	10,000
August 1, 2018	$10,000	12%	Convertible into units of the Company’s common stock on the terms and at a price of the private placement offering open at the time of conversion. Payable on demand.	404	10,404
	$30,500			$1,026	$31,526

(2) Advances Payable

During the six-month period ended November 30, 2018, the Company borrowed $28,871 from unrelated parties. The advances are non-interest bearing, unsecured and payable on demand.

Interest Expense

During the six-month period ended November 30, 2018, the Company recorded $4,790 (2017 - $8,241) in interest expense associated with its liabilities under the notes and advances payable.

XML 27 R15.htm IDEA: XBRL DOCUMENT

Share Capital Disclosure

6 Months Ended

Nov. 30, 2018

Notes

Share Capital Disclosure

NOTE 8 - SHARE CAPITAL

Options

The changes in the number of stock options outstanding during the six-month period ended November 30, 2018, and for the year ended May 31, 2018 are as follows:

	Six months ended November 30, 2018			Year ended May 31, 2018
	Number of options	Weighted average exercise price		Number of options	Weighted average exercise price
Options outstanding, beginning	9,450,000	$	0.35	7,550,000	$	0.35
Options granted	--	$	n/a	2,050,000	$	0.35
Options expired	--	$	n/a	(150,000)	$	0.20
Options cancelled	(2,400,000)	$	0.67	--	$	n/a
Options outstanding, ending	7,050,000	$	0.24	9,450,000	$	0.35

Details of options outstanding and exercisable as at November 30, 2018, are as follows:

Exercise price	Grant date	Number of options Outstanding and exercisable
$0.05	November 25, 2014	2,500,000
$0.35	August 5, 2015	2,500,000
$0.35	August 24, 2017	2,050,000
		7,050,000

At November 30, 2018, the weighted average remaining contractual life of the stock options outstanding was 2.45 years.

Warrants

The changes in the number of warrants outstanding during the six-month period ended November 30, 2018, and for the year ended May 31, 2018 are as follows:

	Six months ended November 30, 2018	Year ended May 31, 2018
Warrants outstanding, beginning	12,814,605	11,094,605
Warrants issued	--	1,720,000
Warrants outstanding, ending	12,814,605	12,814,605

Details of warrants outstanding as at November 30, 2018, are as follows:

Exercise price	Grant Date	Number of warrants exercisable
$0.40 during the period from March 3, 2018 to March 3, 2019 $0.60 during the period from March 3, 2019 to March 3, 2020 $0.75 during the period from March 3, 2020 to March 3, 2021	March 3, 2016	2,000,000
$1.00 during the period from October 12, 2018 to October 12, 2019 $1.25 during the period from October 12, 2019 to October 12, 2020 $1.50 during the period from October 12, 2020 to October 12, 2021	October 12, 2016	9,094,605
$1.00 during the period from October 12, 2018 to October 12, 2019 $1.50 during the period from October 12, 2019 to October 12, 2020	October 12, 2017	1,480,000
$0.50 up to February 7, 2019 $1.00 during the period from February 7, 2019 to February 7, 2020 $1.50 during the period from February 7, 2020 to February 7, 2021	February 7, 2018	240,000
		12,814,605

At November 30, 2018, the weighted average life and price of the warrants was 2.64 years and $0.83, respectively.

XML 28 R16.htm IDEA: XBRL DOCUMENT

Subsequent Event Disclosure

6 Months Ended

Nov. 30, 2018

Notes

Subsequent Event Disclosure

NOTE 9 - SUBSEQUENT EVENT

XML 29 R17.htm IDEA: XBRL DOCUMENT

Organization and Nature of Operations: Going Concern (Policies)

6 Months Ended

Nov. 30, 2018

Policies

Going Concern

Going concern

XML 30 R18.htm IDEA: XBRL DOCUMENT

Related Party Transactions Disclosure: Schedule of Amounts Due to Related Parties (Tables)

6 Months Ended

Nov. 30, 2018

Tables/Schedules

Schedule of Amounts Due to Related Parties

	November 30, 2018		May 31, 2018
Due to the former Chief Executive Officer (“CEO”) and director	$	52,626	$	54,275
Due to a director, CEO and President		54,000		32,400
Due to the Chief Financial Officer (“CFO”)		30,735		20,790
Due to the Vice President (“VP”), Technology and Operations		54,895		59,035
Due to the former Chief Medical Officer		81,059		81,059
Due to the former VP, Corporate Strategy		86,770		86,758
Due to related parties	$	360,085	$	334,317

XML 31 R19.htm IDEA: XBRL DOCUMENT

Related Party Transactions Disclosure: Schedule of Transactions with Related Parties (Tables)

6 Months Ended

Nov. 30, 2018

Tables/Schedules

Schedule of Transactions with Related Parties

	November 30, 2018		November 30, 2017
Management fees incurred to the CEO	$	21,600	$	21,600
Management fees incurred to the CFO		6,000		6,000
Stock-based compensation incurred to the CFO		--		89,556
Consulting fees incurred to the VP, Technology and Operations		25,638		23,475
Stock-based compensation incurred to the Former Chief Medical Officer		--		17,375
Accrued interest expense incurred to the Company’s shareholder (Note 7)		4,294		3,170
Total transactions with related parties	$	57,532	$	161,176

XML 32 R20.htm IDEA: XBRL DOCUMENT

Equipment Disclosure: Amortization schedule for the equipment (Tables)

6 Months Ended

Nov. 30, 2018

Tables/Schedules

Amortization schedule for the equipment

	November 30, 2018		May 31, 2018
Book value, beginning of the period	$	--	$	193,571
Changes during the period		1,915		(193,571)
Amortization		(110)		--
Foreign exchange		(33)		--
Book value, end of the period	$	1,772	$	--

XML 33 R21.htm IDEA: XBRL DOCUMENT

Notes and Advances Payable Disclosure: Schedule of Short-term Loans and Advances Outstanding (Tables)

6 Months Ended

Nov. 30, 2018

Tables/Schedules

Schedule of Short-term Loans and Advances Outstanding

As at November 30, 2018
Principal Outstanding			Interest Rate per Annum					Accrued Interest				Total Book Value
$	29,457		6%		Non-convertible			$		716		$		30,173
	115,964		0%-12%		Former related party⁽¹⁾					8,184				124,148
	40,050		0%		Advances⁽²⁾					--				40,050
$	185,471							$		8,900		$		194,371

As at May 31, 2018
Principal Outstanding				Interest Rate per Annum			Accrued Interest				Total Book Value
$		6,000		6%		Non-convertible	$		225		$		6,225
		95,570		6%-12%		Former related party			4,066				99,636
		11,598		0%		Advances			--				11,598
$		113,168					$		4,291		$		117,459

XML 34 R22.htm IDEA: XBRL DOCUMENT

Notes and Advances Payable Disclosure: Schedule of Former Related Party Loans Payable (Tables)

6 Months Ended

Nov. 30, 2018

Tables/Schedules

Schedule of Former Related Party Loans Payable

Date	Principal (CAD$)	Interest Rate	Additional Terms	Accrued Interest (CAD$)	Total Book Value (CAD$)
June 7, 2018	$10,500	12%	Convertible into units of the Company’s common stock at $0.10 per unit. Includes CAD$500 finance fee, added to principal. Payable on demand.	$622	$11,122
July 3, 2018	$10,000	0%	Short-term loan payable within 14 days after grant. As at November 30, 2018, the loan has not been repaid and therefore was payable on demand.	--	10,000
August 1, 2018	$10,000	12%	Convertible into units of the Company’s common stock on the terms and at a price of the private placement offering open at the time of conversion. Payable on demand.	404	10,404
	$30,500			$1,026	$31,526

XML 35 R23.htm IDEA: XBRL DOCUMENT

Share Capital Disclosure: Schedule of Stock Option Activity (Tables)

6 Months Ended

Nov. 30, 2018

Tables/Schedules

Schedule of Stock Option Activity

	Six months ended November 30, 2018			Year ended May 31, 2018
	Number of options	Weighted average exercise price		Number of options	Weighted average exercise price
Options outstanding, beginning	9,450,000	$	0.35	7,550,000	$	0.35
Options granted	--	$	n/a	2,050,000	$	0.35
Options expired	--	$	n/a	(150,000)	$	0.20
Options cancelled	(2,400,000)	$	0.67	--	$	n/a
Options outstanding, ending	7,050,000	$	0.24	9,450,000	$	0.35

XML 36 R24.htm IDEA: XBRL DOCUMENT

Share Capital Disclosure: Schedule of Stock Options Outstanding (Tables)

6 Months Ended

Nov. 30, 2018

Tables/Schedules

Schedule of Stock Options Outstanding

Exercise price	Grant date	Number of options Outstanding and exercisable
$0.05	November 25, 2014	2,500,000
$0.35	August 5, 2015	2,500,000
$0.35	August 24, 2017	2,050,000
		7,050,000

XML 37 R25.htm IDEA: XBRL DOCUMENT

Share Capital Disclosure: Schedule of Warrant Activity (Tables)

6 Months Ended

Nov. 30, 2018

Tables/Schedules

Schedule of Warrant Activity

	Six months ended November 30, 2018	Year ended May 31, 2018
Warrants outstanding, beginning	12,814,605	11,094,605
Warrants issued	--	1,720,000
Warrants outstanding, ending	12,814,605	12,814,605

XML 38 R26.htm IDEA: XBRL DOCUMENT

Share Capital Disclosure: Schedule of Warrant Details (Tables)

6 Months Ended

Nov. 30, 2018

Tables/Schedules

Schedule of Warrant Details

Exercise price	Grant Date	Number of warrants exercisable
$0.40 during the period from March 3, 2018 to March 3, 2019 $0.60 during the period from March 3, 2019 to March 3, 2020 $0.75 during the period from March 3, 2020 to March 3, 2021	March 3, 2016	2,000,000
$1.00 during the period from October 12, 2018 to October 12, 2019 $1.25 during the period from October 12, 2019 to October 12, 2020 $1.50 during the period from October 12, 2020 to October 12, 2021	October 12, 2016	9,094,605
$1.00 during the period from October 12, 2018 to October 12, 2019 $1.50 during the period from October 12, 2019 to October 12, 2020	October 12, 2017	1,480,000
$0.50 up to February 7, 2019 $1.00 during the period from February 7, 2019 to February 7, 2020 $1.50 during the period from February 7, 2020 to February 7, 2021	February 7, 2018	240,000
		12,814,605

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

XML 39 R27.htm IDEA: XBRL DOCUMENT

Organization and Nature of Operations: Going Concern (Details) - USD ($)	Nov. 30, 2018	May 31, 2018
Details
Accumulated deficit	$ 6,421,823	$ 6,050,841

XML 40 R28.htm IDEA: XBRL DOCUMENT

Related Party Transactions Disclosure: Schedule of Amounts Due to Related Parties (Details) - USD ($)	Nov. 30, 2018	May 31, 2018
Due to related parties	$ 360,085	$ 334,317
Due to the former CEO and Director
Due to related parties	52,626	54,275
Due to a Director and former CEO and President
Due to related parties	54,000	32,400
Due to the CFO
Due to related parties	30,735	20,790
Due to the VP of Technology and Operations
Due to related parties	54,895	59,035
Due to the Chief Medical Officer
Due to related parties	81,059	81,059
Due to the former VP of Corporate Strategy
Due to related parties	$ 86,770	$ 86,758

XML 41 R29.htm IDEA: XBRL DOCUMENT

Related Party Transactions Disclosure: Schedule of Transactions with Related Parties (Details) - USD ($)	6 Months Ended
	Nov. 30, 2018	Nov. 30, 2017
Transactions with related parties	$ 57,532	$ 161,176
Management fees incurred to the CEO
Transactions with related parties	21,600	21,600
Management fees incurred to the CFO
Transactions with related parties	6,000	6,000
Stock-based compensation incurred to the CFO
Transactions with related parties		89,556
Consulting fees incurred to the VP of Technology and Operations
Transactions with related parties	25,638	23,475
Stock-based compensation incurred to the Chief Medical Officer
Transactions with related parties		17,375
Accrued interest expense incurred to a shareholder
Transactions with related parties	$ 4,294	$ 3,170

XML 42 R30.htm IDEA: XBRL DOCUMENT

Inventory Disclosure (Details) - USD ($)	Nov. 30, 2018	May 31, 2018
Inventory	$ 59,787	$ 10,793
Supplies held for resale
Inventory	13,694	$ 10,793
Work in progress was associated with eBalance devices
Inventory	$ 46,093

XML 43 R31.htm IDEA: XBRL DOCUMENT

Other Current Assets Disclosure (Details) - USD ($)	Nov. 30, 2018	May 31, 2018
Other current assets	$ 9,216	$ 26,266
Prepaid expense
Other current assets	2,572	23,915
Receivables associated with GST
Other current assets	$ 6,644	$ 2,351

XML 44 R32.htm IDEA: XBRL DOCUMENT

Equipment Disclosure: Amortization schedule for the equipment (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Nov. 30, 2018	Nov. 30, 2017	Nov. 30, 2018	Nov. 30, 2017	May 31, 2018	May 31, 2017
Details
Equipment, book value	$ 1,772		$ 1,772			$ 193,571
Increase (decrease) in equipment			1,915		$ (193,571)
Amortization	$ 110	$ 38,434	110	$ 77,557
Foreign exchange gain (loss), equipment			$ (33)

XML 45 R33.htm IDEA: XBRL DOCUMENT

Unearned Revenue Disclosure (Details) - USD ($)	Nov. 30, 2018	May 31, 2018
Unearned revenue	$ 301,277	$ 51,585
LOI - Refundable deposit for exclusive worldwide distribution rights
Unearned revenue	$ 250,000

XML 46 R34.htm IDEA: XBRL DOCUMENT

Notes and Advances Payable Disclosure: Schedule of Short-term Loans and Advances Outstanding (Details) - USD ($)	Nov. 30, 2018	May 31, 2018
Principal outstanding	$ 185,471	$ 113,168
Accrued interest/accretion	8,900	4,291
Notes and advances payable	194,371	117,459
Non-convertible loan
Principal outstanding	$ 29,457	$ 6,000
Effective interest rate	6.00%	6.00%
Accrued interest/accretion	$ 716	$ 225
Notes and advances payable	30,173	6,225
Former Related Party, loan
Principal outstanding	$ 115,964	$ 95,570
Effective interest rate	12.00%	12.00%
Accrued interest/accretion	$ 8,184	$ 4,066
Notes and advances payable	124,148	99,636
Advances
Principal outstanding	40,050	11,598
Notes and advances payable	$ 40,050	$ 11,598

XML 47 R35.htm IDEA: XBRL DOCUMENT

Notes and Advances Payable Disclosure (Details) - USD ($)	3 Months Ended		6 Months Ended
	Nov. 30, 2018	Nov. 30, 2017	Nov. 30, 2018	Nov. 30, 2017
Proceeds from notes payable			$ 47,004	$ 25,318
Advances received			28,871
Interest expense	$ 2,648	$ 327	4,790	$ 8,241
Loan agreements - Mr. Jeffs
Proceeds from notes payable			$ 23,029

XML 48 R36.htm IDEA: XBRL DOCUMENT

Share Capital Disclosure: Schedule of Stock Option Activity (Details) - $ / shares	6 Months Ended
	Nov. 30, 2018	May 31, 2018	May 31, 2017
Details
Stock options outstanding	7,050,000	9,450,000	7,550,000
Options outsanding, weighted average exercise price	$ 0.24	$ 0.35	$ 0.35
Options cancelled	(2,400,000)

XML 49 R37.htm IDEA: XBRL DOCUMENT

Share Capital Disclosure: Schedule of Stock Options Outstanding (Details) - $ / shares	12 Months Ended
	May 31, 2018	May 31, 2016	May 31, 2015
Options granted November 25, 2014 (Vendors for Technology)
Exercise price (options)			$ 0.05
Stock options granted			2,500,000
Options granted August 5, 2015 (CEO, President and a member of the board)
Exercise price (options)		$ 0.35
Stock options granted		2,500,000
Options granted August 24, 2017 (CFO and Consultants)
Exercise price (options)	$ 0.35
Stock options granted	2,050,000

XML 50 R38.htm IDEA: XBRL DOCUMENT

Share Capital Disclosure: Schedule of Warrant Activity (Details) - shares	12 Months Ended
	May 31, 2018	Nov. 30, 2018	May 31, 2017
Details
Number of warrants outstanding	12,814,605	12,814,605	11,094,605
Warrants issued	1,720,000

XML 51 R39.htm IDEA: XBRL DOCUMENT

Share Capital Disclosure: Schedule of Warrant Details (Details)	Nov. 30, 2018 shares
Number of warrants exercisable	12,814,605
Warrants granted March 3, 2016
Number of warrants exercisable	2,000,000
Warrants granted October 12, 2016
Number of warrants exercisable	9,094,605
Warrants granted October 12, 2017
Number of warrants exercisable	1,480,000
Warrants granted February 7, 2018
Number of warrants exercisable	240,000

XML 52 R40.htm IDEA: XBRL DOCUMENT

Subsequent Event Disclosure (Details) - USD ($)	1 Months Ended	12 Months Ended
Subsequent Event Disclosure (Details) - USD ($)	Dec. 20, 2018	May 31, 2018
Warrants issued		1,720,000
Credit Line Agreement with Mr. Jeffs
Unsecured Line of Credit, Agreement amount	$ 250,000
Proceeds from Lines of Credit	$ 100,000
Warrants issued	5,000,000
Loan Agreement with Mr. Jeffs
Warrants issued	2,482,960

- Definition

The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.

+ References + Details

EXCEL 53 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 55 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 57 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 88 117 1 false 36 0 false 4 false false R1.htm 000010 - Document - Document and Entity Information Sheet http://www.cellmedx.com/20181130/role/idr_DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 000020 - Statement - Consolidated Balance Sheets Sheet http://www.cellmedx.com/20181130/role/idr_ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 000030 - Statement - Balance Sheets (Parenthetical) Sheet http://www.cellmedx.com/20181130/role/idr_BalanceSheetsParenthetical Balance Sheets (Parenthetical) Statements 3 false false R4.htm 000040 - Statement - Consolidated Statements of Operations Sheet http://www.cellmedx.com/20181130/role/idr_ConsolidatedStatementsOfOperations Consolidated Statements of Operations Statements 4 false false R5.htm 000050 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) Sheet http://www.cellmedx.com/20181130/role/idr_ConsolidatedStatementsOfStockholdersEquityDeficit Consolidated Statements of Stockholders' Equity (Deficit) Statements 5 false false R6.htm 000060 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical) Sheet http://www.cellmedx.com/20181130/role/idr_ConsolidatedStatementsOfStockholdersEquityParenthetical Consolidated Statements of Stockholders' Equity (Parenthetical) Statements 6 false false R7.htm 000070 - Statement - Consolidated Statements of Cash Flows Sheet http://www.cellmedx.com/20181130/role/idr_ConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows Statements 7 false false R8.htm 000080 - Disclosure - Organization and Nature of Operations Sheet http://www.cellmedx.com/20181130/role/idr_DisclosureOrganizationAndNatureOfOperations Organization and Nature of Operations Notes 8 false false R9.htm 000090 - Disclosure - Related Party Transactions Disclosure Sheet http://www.cellmedx.com/20181130/role/idr_DisclosureRelatedPartyTransactionsDisclosure Related Party Transactions Disclosure Notes 9 false false R10.htm 000100 - Disclosure - Inventory Disclosure Sheet http://www.cellmedx.com/20181130/role/idr_DisclosureInventoryDisclosure Inventory Disclosure Notes 10 false false R11.htm 000110 - Disclosure - Other Current Assets Disclosure Sheet http://www.cellmedx.com/20181130/role/idr_DisclosureOtherCurrentAssetsDisclosure Other Current Assets Disclosure Notes 11 false false R12.htm 000120 - Disclosure - Equipment Disclosure Sheet http://www.cellmedx.com/20181130/role/idr_DisclosureEquipmentDisclosure Equipment Disclosure Notes 12 false false R13.htm 000130 - Disclosure - Unearned Revenue Disclosure Sheet http://www.cellmedx.com/20181130/role/idr_DisclosureUnearnedRevenueDisclosure Unearned Revenue Disclosure Notes 13 false false R14.htm 000140 - Disclosure - Notes and Advances Payable Disclosure Notes http://www.cellmedx.com/20181130/role/idr_DisclosureNotesAndAdvancesPayableDisclosure Notes and Advances Payable Disclosure Notes 14 false false R15.htm 000150 - Disclosure - Share Capital Disclosure Sheet http://www.cellmedx.com/20181130/role/idr_DisclosureShareCapitalDisclosure Share Capital Disclosure Notes 15 false false R16.htm 000160 - Disclosure - Subsequent Event Disclosure Sheet http://www.cellmedx.com/20181130/role/idr_DisclosureSubsequentEventDisclosure Subsequent Event Disclosure Notes 16 false false R17.htm 000170 - Disclosure - Organization and Nature of Operations: Going Concern (Policies) Sheet http://www.cellmedx.com/20181130/role/idr_DisclosureOrganizationAndNatureOfOperationsGoingConcernPolicies Organization and Nature of Operations: Going Concern (Policies) Policies 17 false false R18.htm 000180 - Disclosure - Related Party Transactions Disclosure: Schedule of Amounts Due to Related Parties (Tables) Sheet http://www.cellmedx.com/20181130/role/idr_DisclosureRelatedPartyTransactionsDisclosureScheduleOfAmountsDueToRelatedPartiesTables Related Party Transactions Disclosure: Schedule of Amounts Due to Related Parties (Tables) Tables 18 false false R19.htm 000190 - Disclosure - Related Party Transactions Disclosure: Schedule of Transactions with Related Parties (Tables) Sheet http://www.cellmedx.com/20181130/role/idr_DisclosureRelatedPartyTransactionsDisclosureScheduleOfTransactionsWithRelatedPartiesTables Related Party Transactions Disclosure: Schedule of Transactions with Related Parties (Tables) Tables 19 false false R20.htm 000200 - Disclosure - Equipment Disclosure: Amortization schedule for the equipment (Tables) Sheet http://www.cellmedx.com/20181130/role/idr_DisclosureEquipmentDisclosureAmortizationScheduleForTheEquipmentTables Equipment Disclosure: Amortization schedule for the equipment (Tables) Tables 20 false false R21.htm 000210 - Disclosure - Notes and Advances Payable Disclosure: Schedule of Short-term Loans and Advances Outstanding (Tables) Notes http://www.cellmedx.com/20181130/role/idr_DisclosureNotesAndAdvancesPayableDisclosureScheduleOfShortTermLoansAndAdvancesOutstandingTables Notes and Advances Payable Disclosure: Schedule of Short-term Loans and Advances Outstanding (Tables) Tables 21 false false R22.htm 000220 - Disclosure - Notes and Advances Payable Disclosure: Schedule of Former Related Party Loans Payable (Tables) Notes http://www.cellmedx.com/20181130/role/idr_DisclosureNotesAndAdvancesPayableDisclosureScheduleOfFormerRelatedPartyLoansPayableTables Notes and Advances Payable Disclosure: Schedule of Former Related Party Loans Payable (Tables) Tables 22 false false R23.htm 000230 - Disclosure - Share Capital Disclosure: Schedule of Stock Option Activity (Tables) Sheet http://www.cellmedx.com/20181130/role/idr_DisclosureShareCapitalDisclosureScheduleOfStockOptionActivityTables Share Capital Disclosure: Schedule of Stock Option Activity (Tables) Tables 23 false false R24.htm 000240 - Disclosure - Share Capital Disclosure: Schedule of Stock Options Outstanding (Tables) Sheet http://www.cellmedx.com/20181130/role/idr_DisclosureShareCapitalDisclosureScheduleOfStockOptionsOutstandingTables Share Capital Disclosure: Schedule of Stock Options Outstanding (Tables) Tables 24 false false R25.htm 000250 - Disclosure - Share Capital Disclosure: Schedule of Warrant Activity (Tables) Sheet http://www.cellmedx.com/20181130/role/idr_DisclosureShareCapitalDisclosureScheduleOfWarrantActivityTables Share Capital Disclosure: Schedule of Warrant Activity (Tables) Tables 25 false false R26.htm 000260 - Disclosure - Share Capital Disclosure: Schedule of Warrant Details (Tables) Sheet http://www.cellmedx.com/20181130/role/idr_DisclosureShareCapitalDisclosureScheduleOfWarrantDetailsTables Share Capital Disclosure: Schedule of Warrant Details (Tables) Tables 26 false false R27.htm 000270 - Disclosure - Organization and Nature of Operations: Going Concern (Details) Sheet http://www.cellmedx.com/20181130/role/idr_DisclosureOrganizationAndNatureOfOperationsGoingConcernDetails Organization and Nature of Operations: Going Concern (Details) Details http://www.cellmedx.com/20181130/role/idr_DisclosureOrganizationAndNatureOfOperationsGoingConcernPolicies 27 false false R28.htm 000280 - Disclosure - Related Party Transactions Disclosure: Schedule of Amounts Due to Related Parties (Details) Sheet http://www.cellmedx.com/20181130/role/idr_DisclosureRelatedPartyTransactionsDisclosureScheduleOfAmountsDueToRelatedPartiesDetails Related Party Transactions Disclosure: Schedule of Amounts Due to Related Parties (Details) Details http://www.cellmedx.com/20181130/role/idr_DisclosureRelatedPartyTransactionsDisclosureScheduleOfAmountsDueToRelatedPartiesTables 28 false false R29.htm 000290 - Disclosure - Related Party Transactions Disclosure: Schedule of Transactions with Related Parties (Details) Sheet http://www.cellmedx.com/20181130/role/idr_DisclosureRelatedPartyTransactionsDisclosureScheduleOfTransactionsWithRelatedPartiesDetails Related Party Transactions Disclosure: Schedule of Transactions with Related Parties (Details) Details http://www.cellmedx.com/20181130/role/idr_DisclosureRelatedPartyTransactionsDisclosureScheduleOfTransactionsWithRelatedPartiesTables 29 false false R30.htm 000300 - Disclosure - Inventory Disclosure (Details) Sheet http://www.cellmedx.com/20181130/role/idr_DisclosureInventoryDisclosureDetails Inventory Disclosure (Details) Details http://www.cellmedx.com/20181130/role/idr_DisclosureInventoryDisclosure 30 false false R31.htm 000310 - Disclosure - Other Current Assets Disclosure (Details) Sheet http://www.cellmedx.com/20181130/role/idr_DisclosureOtherCurrentAssetsDisclosureDetails Other Current Assets Disclosure (Details) Details http://www.cellmedx.com/20181130/role/idr_DisclosureOtherCurrentAssetsDisclosure 31 false false R32.htm 000320 - Disclosure - Equipment Disclosure: Amortization schedule for the equipment (Details) Sheet http://www.cellmedx.com/20181130/role/idr_DisclosureEquipmentDisclosureAmortizationScheduleForTheEquipmentDetails Equipment Disclosure: Amortization schedule for the equipment (Details) Details http://www.cellmedx.com/20181130/role/idr_DisclosureEquipmentDisclosureAmortizationScheduleForTheEquipmentTables 32 false false R33.htm 000330 - Disclosure - Unearned Revenue Disclosure (Details) Sheet http://www.cellmedx.com/20181130/role/idr_DisclosureUnearnedRevenueDisclosureDetails Unearned Revenue Disclosure (Details) Details http://www.cellmedx.com/20181130/role/idr_DisclosureUnearnedRevenueDisclosure 33 false false R34.htm 000340 - Disclosure - Notes and Advances Payable Disclosure: Schedule of Short-term Loans and Advances Outstanding (Details) Notes http://www.cellmedx.com/20181130/role/idr_DisclosureNotesAndAdvancesPayableDisclosureScheduleOfShortTermLoansAndAdvancesOutstandingDetails Notes and Advances Payable Disclosure: Schedule of Short-term Loans and Advances Outstanding (Details) Details http://www.cellmedx.com/20181130/role/idr_DisclosureNotesAndAdvancesPayableDisclosureScheduleOfShortTermLoansAndAdvancesOutstandingTables 34 false false R35.htm 000350 - Disclosure - Notes and Advances Payable Disclosure (Details) Notes http://www.cellmedx.com/20181130/role/idr_DisclosureNotesAndAdvancesPayableDisclosureDetails Notes and Advances Payable Disclosure (Details) Details http://www.cellmedx.com/20181130/role/idr_DisclosureNotesAndAdvancesPayableDisclosureScheduleOfShortTermLoansAndAdvancesOutstandingTables 35 false false R36.htm 000360 - Disclosure - Share Capital Disclosure: Schedule of Stock Option Activity (Details) Sheet http://www.cellmedx.com/20181130/role/idr_DisclosureShareCapitalDisclosureScheduleOfStockOptionActivityDetails Share Capital Disclosure: Schedule of Stock Option Activity (Details) Details http://www.cellmedx.com/20181130/role/idr_DisclosureShareCapitalDisclosureScheduleOfStockOptionActivityTables 36 false false R37.htm 000370 - Disclosure - Share Capital Disclosure: Schedule of Stock Options Outstanding (Details) Sheet http://www.cellmedx.com/20181130/role/idr_DisclosureShareCapitalDisclosureScheduleOfStockOptionsOutstandingDetails Share Capital Disclosure: Schedule of Stock Options Outstanding (Details) Details http://www.cellmedx.com/20181130/role/idr_DisclosureShareCapitalDisclosureScheduleOfStockOptionsOutstandingTables 37 false false R38.htm 000380 - Disclosure - Share Capital Disclosure: Schedule of Warrant Activity (Details) Sheet http://www.cellmedx.com/20181130/role/idr_DisclosureShareCapitalDisclosureScheduleOfWarrantActivityDetails Share Capital Disclosure: Schedule of Warrant Activity (Details) Details http://www.cellmedx.com/20181130/role/idr_DisclosureShareCapitalDisclosureScheduleOfWarrantActivityTables 38 false false R39.htm 000390 - Disclosure - Share Capital Disclosure: Schedule of Warrant Details (Details) Sheet http://www.cellmedx.com/20181130/role/idr_DisclosureShareCapitalDisclosureScheduleOfWarrantDetailsDetails Share Capital Disclosure: Schedule of Warrant Details (Details) Details http://www.cellmedx.com/20181130/role/idr_DisclosureShareCapitalDisclosureScheduleOfWarrantActivityTables 39 false false R40.htm 000400 - Disclosure - Subsequent Event Disclosure (Details) Sheet http://www.cellmedx.com/20181130/role/idr_DisclosureSubsequentEventDisclosureDetails Subsequent Event Disclosure (Details) Details http://www.cellmedx.com/20181130/role/idr_DisclosureSubsequentEventDisclosure 40 false false All Reports Book All Reports cmxc-20181130.xml cmxc-20181130.xsd cmxc-20181130_cal.xml cmxc-20181130_def.xml cmxc-20181130_lab.xml cmxc-20181130_pre.xml http://xbrl.sec.gov/dei/2014-01-31 http://fasb.org/us-gaap/2017-01-31 true true ZIP 59 0001393905-19-000016-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001393905-19-000016-xbrl.zip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end